

<b>Semir Vranić, M.D., Ph.D.</b>	
<b>Business address</b>	College of Medicine, Qatar University Doha 2713, Doha, Qatar E-mail: <a href="mailto:semir.vranic@gmail.com">semir.vranic@gmail.com</a> , <a href="mailto:semir.vranic@bosnianpathology.org">semir.vranic@bosnianpathology.org</a> , <a href="mailto:svranic@qu.edu.qa">svranic@qu.edu.qa</a>
<b>Date and place of birth</b>	October 10, 1974, Bosnia and Herzegovina
<b>Citizenship</b>	Bosnia and Herzegovina
<b>Education</b>	1997-2004, School of Medicine, University of Sarajevo 2004, December 22: M.D. degree, School of Medicine, University of Sarajevo 2006, January 25: License for clinical practice in Bosnia and Herzegovina 2006-2012. PhD study. Zagreb University School of Medicine, Zagreb, Croatia 2007-2011. Residency. Anatomic Pathology, University of Sarajevo 2008/2009: Research fellow of UICC/ACS at the Creighton University School of Medicine, Omaha, NE, United States of America 2011, December 17: Pathologist (Board Certified, Bosnia and Herzegovina) 2012, September 14: Ph.D. degree, Zagreb University School of Medicine (Croatia) 2012/2013: Post-doc fellowship at the University of Turin, Italy
<b>Appointments</b>	2005/2006: Internship, Clinical Center of the University of Sarajevo 2006-2007/2009-2011: Resident, Department of Pathology, Clinical Center of the University of Sarajevo 2008/2009: Research fellow of UICC/ACS, Creighton University Medical School, Omaha, NE, United States of America 2012-2017: Staff Pathologist, Clinical Center of the University of Sarajevo 2012/2013: Post-doc researcher, University of Turin, Italy 2013: Assistant Research Scientist, Zagreb University School of Medicine 2014-2020: Consultant, Caris Life Sciences, Phoenix, Arizona, United States of America 2016-2017: Assistant professor of pathology, School of Medicine, University of Sarajevo 2016-2017: Member of the Council for Science and Art, University of Sarajevo 2017-2020: Assistant professor of pathology, College of Medicine, Qatar University 2021: Associate professor of pathology, College of Medicine, Qatar University 2022: Corresponding member of the Academy of Sciences and Arts of Bosnia and Herzegovina
	<p><b>Researcher (2003-):</b> Anatomic pathology, immunohistochemistry, in situ hybridization, cell culture, Western Blot, MLPA, molecular profiling of cancer</p> <p><b>Research fellow (2008-2010):</b> Creighton University Medical Center, Department of Pathology, Omaha, Nebraska, United States of America</p> <p><b>Post-doc researcher (2012-2013):</b> University of Turin (Italy)</p> <p><b>Consultant (2014-2020):</b> Caris Life Sciences (Phoenix, AZ, USA)</p> <p><b>Organization and administrative skills:</b></p> <ul style="list-style-type: none"> <li>• Founder and course coordinator of the Bosnian-British School of Pathology (<b>Bryan Warren School of Pathology</b>) (since 2006-) <a href="https://www.bosnianpathology.org/pathology-school/introduction">https://www.bosnianpathology.org/pathology-school/introduction</a></li> </ul>

<b>Experience</b>	<ul style="list-style-type: none"> <li>• One of the organizers of the <b>Bosnian Turkish School of Cytopathology</b> (since 2016-) <a href="https://www.bosnianpathology.org/cytopathology-school/introduction">https://www.bosnianpathology.org/cytopathology-school/introduction</a></li> <li>• President of the Association of Pathologist and Cytologists of Federation of Bosnia and Herzegovina (2015-2017)</li> <li>• Vice president of the Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina (2015-)</li> </ul> <p><b>Journal editor positions and editorial board member:</b>  <b>Bosnian Journal of Basic Medical Sciences</b> (section editor and editor in chief, 2014-)  <b>Breast Cancer: Targets and Therapy</b> (consulting editor, 2015-2019)  <b>Journal of Laboratory Physicians:</b> Editorial board member, 2012-2019; Associate editor (2019-)  <b>Annals of Translational Medicine:</b> Editorial board member, November 2017- December 2021  <b>PLOS One:</b> Academic editor (2018-)  <b>Cancer Cell International:</b> Associate editor (January 2019 – July 2020)  <b>Acta Medica Academica:</b> Editorial board member (2020-)  <b>Central European Journal of Paediatrics:</b> Editorial board member (2020-)</p> <p><b>Peer-review activities</b></p> <p><b>a) Biomedical journals (&gt;90), 2011-):</b>  BMC Cancer, Pathology Research &amp; Practice, Croatian Medical Journal, Frontiers in Bioscience, Molecular Medicine, Cancer Letters, Expert Reviews of Molecular Diagnostics, PLoS One, Oncotarget, International Journal of Nanomedicine, Drug Design, Development and Therapy, International Journal of Surgical Pathology, World Journal of Surgical Oncology, Journal of International Medical Research, Diagnostic Cytopathology, Journal of Obstetrics and Gynaecology, Cell Biology and Toxicology, Expert Opinion on Biological Therapy, Future Oncology, Chinese Journal of Cancer Research, Histopathology, APMIS, Diagnostic Pathology, Journal of Drug Targeting, Journal of Laboratory Physicians, Breast Disease, BMC Clinical Pathology, Breast Cancer: Targets and Therapy, OncoTargets and Therapy, Clinical Epidemiology, Journal for ImmunoTherapy of Cancer, Case Reports in Pathology, Current Oncology, Journal of Thoracic Disease, Polish Journal of Pathology, Indian Journal of Medical Research, Journal of Cancer Research and Therapeutics, Journal of Neurosciences in Rural Practice, International Medical Case Reports Journal, Acta Clinica Croatica, Bosnian Journal of Basic Medical Sciences, Archives of International Surgery, Clinical Cancer Investigation Journal, Chronic Diseases and Translational Medicine, Personalized Medicine, Cancer Cell International, Annals of Translational Medicine, Molecular Oncology, Frontiers in Oncology, Heliyon, Oxford Medical Case Reports, Gene, Cancers, Tumor Biology, Medical Science Monitor, Journal of Thoracic Disease, Frontiers of Medicine, Journal of Pathology, Current Molecular Medicine, Applied Immunohistochemistry and Molecular Morphology, Case Reports in Oncological Medicine, Clinical Breast Cancer, DNA and Cell Biology, Clinical Medicine Insights: Oncology, Oncology Letters, Acta Medica Croatica, Acta Medica Academica, European Journal of Pharmacology, International Journal of Molecular Sciences, Cancer Medicine, Acta Biochimica Polonica, Immunotherapy, Molecular Biology Reports, Journal of Oncology, Hepatobiliary and Pancreatic Diseases International, Eurasian Journal of Medical Investigation, Cancer Immunology Research, F1000Research, Current Drug Targets, SN Comprehensive Clinical Medicine; JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Pathology and Oncology Research, Biocell,</p>
-------------------	---

	<p>European Journal of Endocrinology, Pathobiology, Breast Cancer: Basic and Clinical Research, Clinical Genitourinary Cancer, The Breast, Current Microbiology, Viruses (Basel), NPJ Breast Cancer (Nature Springer), Journal of Egyptian National Cancer Institute, International Journal of Cancer, Cancer Communications, Gland Surgery, Biomarkers.</p> <p><b>b) External peer-reviews for institutions and research agencies</b></p> <ul style="list-style-type: none"> <li>• Agency for Health Quality and Assessment of Catalonia (Barcelona, Spain) (2017-2020)</li> <li>• Breast Cancer Now (United Kingdom) (2019)</li> <li>• University of Vienna (Austria) (2020-)</li> <li>• “La Caixa” Foundation (Palma, Spain) (2020-)</li> </ul> <p><b>Mentorship/Supervision:</b></p> <ul style="list-style-type: none"> <li>- Two PhD students (Dr. Faruk Skenderi, completed PhD at the University of Zagreb, September 2021; Dr. Ana Parić, PhD Student, University of Mostar School of Medicine, 2023-)</li> <li>- Three graduate/master students (2014-2017, University of Sarajevo and University of Zagreb)</li> <li>- One early career researcher (Dr. Hamda Al Thawadi, Qatar University, 2022-24, co-supervisor)</li> </ul>
<p><b>Scientific/ research interests</b></p>	<p>Breast cancer pathology (special types) Genitourinary pathology Hereditary cancer syndromes Molecular pathology of rare tumors Precision medicine biomarkers Scientific writing, academic publishing</p>
<p><b>Language skills</b></p>	<p>Bosnian (native) English Danish</p>
<p><b>Teaching and course coordination responsibilities</b></p>	<p><b>Undergraduate medical students (2014-)</b></p> <ol style="list-style-type: none"> <li>1. <b>General pathology courses covering:</b> <ol style="list-style-type: none"> <li>a) Fundamentals of cancer cell biology and pathology</li> <li>b) Cancer genetics and molecular pathology</li> <li>c) Introduction to hereditary and developmental diseases</li> </ol> </li> <li>2. <b>Systems pathology covering:</b> <ol style="list-style-type: none"> <li>a) Breast cancer pathology</li> <li>b) Genitourinary pathology</li> <li>c) Reproductive pathology</li> <li>d) Endocrine pathology</li> <li>e) Thyroid gland pathology</li> <li>f) Pulmonary and mediastinal pathology</li> <li>g) Neuroscience and neuromuscular pathology</li> </ol> </li> </ol> <p><b>Problem based learning (PBL), College of Medicine, Qatar University (2017-)</b></p> <ul style="list-style-type: none"> <li>• Involved in tutoring small groups of medical students</li> <li>• Writing case problems and coordinating cases</li> <li>• Writing multiple choice questions (MCQ)</li> </ul>

	<p><b>Graduate/Postgraduate medical students</b></p> <ul style="list-style-type: none"> <li>• Master thesis (2 students) (supervisor)</li> <li>• PhD thesis (2 students) (supervisor/co-supervisor)</li> <li>• Postdoctoral candidates (1 candidate) (co-supervisor) (<u>ECRA3: Early Career Researchers – 3rd cycle, Qatar University 2021</u>)</li> </ul> <p><b>Postgraduate (PhD) courses:</b></p> <p><b>Qatar University College of Medicine and College of Health Sciences (2018-):</b></p> <ol style="list-style-type: none"> <li>1. <u>Advanced Research Methods (Course BIOM 700)</u>: Methods in microscopy and sample preparations: light microscopy, fluorescence microscopy, confocal microscopy</li> <li>2. <u>Clinical translational research (Course MEDI 720)</u>: The role of pathology in cancer research</li> <li>3. <u>Cellular and molecular basis of disease (Course QUHC710)</u>: The role of pathology in precision medicine (biomarkers)</li> <li>4. <u>Oncology (Course BIOM680)</u>: Pathology of Cancer; Novel predictive biomarkers for targeted cancer therapy (2020-2021)</li> <li>5. <u>QUHC710 - Molecular basis of Carcinogenesis II: Molecular pathology of common cancers (2022-)</u></li> </ol> <p><b>University of Tuzla School of Medicine (Bosnia and Herzegovina) (2019-):</b></p> <ol style="list-style-type: none"> <li>1. <u>Basic Science Research in Biomedicine</u> (The role of pathology in precision medicine; The role of pathology in cancer research; Pathology of tumors; Scientific publishing: the role of predatory journals)</li> <li>2. <u>Clinical Oncology</u> (Advances in molecular pathology of the breast cancer)</li> </ol>
<p><b>Awards and scholarships</b></p>	<p>2007. Fellowship for one month training program in a European Breast Unit in 2008 by the European Society of Mastology (EUSOMA), Nottingham (UK)</p> <p>2008. Fellowship from the American Cancer Society/UICC for beginning researcher (Omaha, NE, USA), October 2008-October 2009</p> <p>2012. Fellowship from the British Division of the International Academy of Pathology (BDIAP) for the breast pathology training at the Guy’s Hospital, London (November 2012).</p> <p>2012. Post-doc Fellowship at the University of Turin (Italy), 2012-2013, Erasmus University Rotterdam, Netherlands</p> <p>2012. University of Zagreb School of Medicine: Award for the most productive PhD</p> <p>2016. The Pathologist: “Power List 2016” (The “rising stars” in pathology)</p> <p>2020. Academic Research Award, College of Medicine, Qatar University</p> <p><b>2021-2022. Top 2% of the world's most cited scientists (Stanford University Study)</b></p>
<p><b>Grants (from 2018)</b></p>	<ol style="list-style-type: none"> <li>1. The expression of the Hedgehog signaling pathway components Gli1, Gli3 and PTCH1 in invasive apocrine carcinoma of the breast (<b>Lead PI, funded by Qatar University, 2018-2019, 25,000€</b>)</li> <li>2. The role and contribution of predatory pathology journals and publishers in academic medical pathology (<b>Lead PI, funded by Qatar University, 2018-2019, 2500€</b>)</li> <li>3. Effect of Truffle extract on Triple-Negative Human Breast Cancer Cells: A pilot study (<b>Lead PI, funded by Qatar University, 2018-2019, 2500€</b>)</li> <li>4. Gene expression profiling of triple-negative breast cancer in Qatari women (<b>Co-PI, funded by Qatar University, 2019, 25,000€</b>)</li> <li>5. Prevalence and genotype distribution of human papillomaviruses in rectal cancer in the Middle East region (<b>Co-PI, funded by Qatar University, 2019-2020, 132,000€</b>)</li> </ol>

	<ol style="list-style-type: none"> <li>6. Epstein-Barr virus and Helicobacter Pylori in oral cancer: A new concept of oncoviruses/oncobacteria cooperation in human carcinogenesis (<b>Lead PI, funded by Qatar University, 2020-2021, 74,000€</b>)</li> <li>7. MiRNA profiles of HER2-positive breast cancer with brain metastasis (<b>Lead PI, funded by Qatar University, 2021-2022, 65,000\$</b>)</li> <li>8. Role of HCN, Kv7 and A-type Potassium Channels in Diabetic Peripheral Neuropathic Pain (<b>Co-PI, National Priorities Research Program - Standard (NPRP-S) 13th Cycle, 2021-2023, 486,000\$</b>)</li> <li>9. Diabetes and colorectal cancer – molecular risk association, characterization of mechanisms and identification of molecular signature(s)/biomarker(s) (<b>Co-PI, National Priorities Research Program - Standard (NPRP-S) 14th Cycle, 2023-2027, 450,000\$</b>)</li> <li>10. ECRA3: Early Career Researchers – 3rd cycle (<b>co-mentor for Dr. Hamda Al Thawadi, 330,000 US\$, 2022-2023, funded by Qatar National Research Foundation/QNRF/</b>)</li> </ol>
<p><b>International congresses, seminars, education (past 5 years)</b></p>	<p><b>(2016)</b></p> <ul style="list-style-type: none"> <li>• USCAP Annual meeting, 14-18 March, Seattle, USA</li> <li>• 1<sup>st</sup> Bosnian-Turkish School of Cytopathology, Sarajevo, 18-19 June</li> <li>• 40<sup>th</sup> ESMO Congress, Copenhagen, October 7-11</li> <li>• Treći kongres patologa Bosne i Hercegovine sa međunarodnim učešćem, Sarajevo, 2-3 November</li> <li>• 10<sup>th</sup> Bryan Warren School of Pathology, November 4-5</li> <li>• 2<sup>nd</sup> Winter Oncology Symposium, Sarajevo, 9-11 December</li> </ul> <p><b>(2017)</b></p> <ul style="list-style-type: none"> <li>• USCAP Annual meeting, 4-10 March, San Antonio, Texas, USA</li> <li>• 2 day PD-L1 testing in NSCLC, Expert course, Targos, Kassel, March 14-15, 2017</li> <li>• 2<sup>nd</sup> Bosnian Turkish School of Cytopathology, Sarajevo, May 6-7</li> <li>• Ljudevit Jurak Symposium on Comparative Pathology, June 2, Zagreb, Croatia</li> <li>• 11<sup>th</sup> Bryan Warren School of Pathology, November 4-5, Sarajevo</li> </ul> <p><b>(2018)</b></p> <ul style="list-style-type: none"> <li>• USCAP Annual meeting, 17-23 March, Vancouver, Canada</li> <li>• Genitourinary Pathology Course, April 26-27, Sarajevo, Bosnia and Herzegovina</li> <li>• 3<sup>rd</sup> Bosnian Turkish School of Cytopathology, June 23, Sarajevo, Bosnia and Herzegovina</li> <li>• 2nd ROS Meeting, July 6-8, 2018, Munich, Germany</li> <li>• 12<sup>th</sup> Bryan Warren School of Pathology, November 3-4, Sarajevo, Bosnia and Herzegovina</li> <li>• 8<sup>th</sup> Middle East Cancer Conference, 8-9 December, Muscat, Oman</li> </ul> <p><b>(2019)</b></p> <ul style="list-style-type: none"> <li>• USCAP Annual meeting, 16-22 March, National Harbor, MD, USA</li> <li>• ESMO Breast Cancer Conference, May 2-4, Berlin, Germany</li> <li>• 4<sup>th</sup> Bosnian Turkish Cytopathology School, May 18-19, Sarajevo, Bosnia and Herzegovina</li> <li>• 27<sup>th</sup> Ljudevit Jurak International Symposium on Comparative Pathology, 31 May – 1 June, Zagreb, Croatia</li> <li>• ESMO annual meeting, September 27 – October 1, Barcelona, Spain</li> <li>• 13<sup>th</sup> Bryan Warren School of Pathology, November 2-3, Sarajevo, Bosnia and Herzegovina</li> <li>• 9<sup>th</sup> Middle East Cancer Conference, 7-8 December, Doha, Qatar</li> </ul> <p><b>(2020)</b></p> <ul style="list-style-type: none"> <li>• USCAP Annual meeting, 28 Feb – 5 March, Los Angeles, CA, USA</li> <li>• ESMO Breast Cancer 2020, May 23-24 (Virtual)</li> </ul>

	<ul style="list-style-type: none"> <li>• An Update on Diagnostic Challenges in Breast Pathology, September 8 (Virtual).</li> <li>• Adriatic PD-L1 experience exchange (Webinar), October 20 (Virtual)</li> <li>• The 6th BDIAP Molecular Pathology Study Day, November 10 (Virtual)</li> <li>• 32nd ESP Congress &amp; XXXIII IAP Congress , 6-8 December (Virtual)</li> </ul> <p><b>(2021)</b></p> <ul style="list-style-type: none"> <li>• 5<sup>th</sup> Bosnian Turkish Cytopathology School, 29 May, Zoom platform (virtual).</li> <li>• Manchester Pathology 2021, July 6-8 (Virtual)</li> <li>• 8th Annual Congress of the European Society for Translational Medicine (EUSTM-2021) 20-26 September, 2021 (Virtual Congress)</li> <li>• 14<sup>th</sup> Bryan Warren School of Pathology, November 6 (virtual)</li> <li>• 11<sup>th</sup> MEACR Meeting, November 27 (virtual)</li> </ul> <p><b>(2022)</b></p> <ul style="list-style-type: none"> <li>• Virtual BDIAP Molecular Pathology Study Day, BDIAP, March 7, 2022 (virtual)</li> <li>• USCAP Annual meeting, 19-23 March, Los Angeles, CA, USA</li> <li>• 6<sup>th</sup> Bosnian Turkish Cytopathology School, May 29 (Virtual, Zoom)</li> <li>• 34<sup>th</sup> European Congress of Pathology, September 3-7, Basel, Switzerland</li> <li>• 15<sup>th</sup> Bryan Warren School of Pathology, November 5 (Virtual event)</li> <li>• 12<sup>th</sup> MEAACR Annual Meeting, December 16-17 (Virtual)</li> </ul>
<p><b>Memberships</b></p>	<p>European Association for Cancer Research (2005-)  European Society of Pathology (ESP) (2006-)  Clinical Genetic Society of Croatia (2007-)  United States &amp; Canadian Academy of Pathology (2010-)  <b>Fellow and Life Member of International Union Against Cancer (UICC) (2010-)</b>  The European Network of Uropathology (2011-2015)  ESP Working Group for Breast Pathology (2011-2017)  World Association of Medical Editors (2015-)  Council of Science Editors (2015-2018)  Association of Basic Medical Sciences of Federation of B&amp;H (2015-)  Association of Pathologists and Cytologists of Federation of B&amp;H (2015-)  COPE (Committee on Publication Ethics) (2016-)  <b>Academy of Sciences and Arts of Bosnia and Herzegovina (corresponding member) (December 2022)</b></p>
<p><b>Invited lectures</b></p>	<ol style="list-style-type: none"> <li>1. "Molecular Pathology of Ovarian Carcinoma with Morphologic Correlation", Seminar: Cervical and Ovarian Carcinoma. European Society of Gynecological Oncology &amp; Udruženje onkologa BiH, Sarajevo, Sept. 14-15, 2007.</li> <li>2. „Special types of breast carcinomas: Is apocrine carcinoma fulfilling the requirements?“ Creighton University School of Medicine, Omaha, NE, USA, September 22, 2009.</li> <li>3. „Hereditary cancer syndromes of the breast and colon“. Clinical Genetic Society of Croatia &amp; Zagreb University School of Medicine, Zagreb, Croatia, November 17, 2009.</li> <li>4. „Molecular pathology of breast cancer“, Symposium „Genetika u medicinskoj praksi“, Sarajevo, October 19, 2010.</li> <li>5. „Predictive markers in ER/PR negative breast carcinomas“. Simpozij „Savremeni tretman karcinoma dojke“, Akademija nauka i umjetnosti Bosne i Hercegovine, Sarajevo, November 23, 2011.</li> <li>6. "The role of genetic testing in management of breast cancer", 4<sup>th</sup> Days of the Bosnian-Herzegovinian-American Academy of Sciences and Arts, Sarajevo, April 19, 2012.</li> </ol>

7. "Breast cancer and microenvironment", Acidox meeting, Munich, Germany, December 3-4, 2013.
8. "The role of pathology in multidisciplinary management of breast cancer", "Onkoplastika dojke", Sarajevo, 7. februar 2014.
9. "Breast Cancer Pathology Update", 6<sup>th</sup> Days of the Bosnian-Herzegovinian-American Academy of Sciences and Arts, Bihać, May 22, 2014.
10. "Prediktivni markeri u eri ciljane terapije karcinoma dojke", 7<sup>th</sup> Days of the Bosnian-Herzegovinian-American Academy of Sciences and Arts, Brčko, April 23, 2015.
11. "Uticaj grešaka u preanalitičkoj fazi na interpretaciju rezultata", Stručni sastanak "Biomarker testiranje u Bosni i Hercegovini", Konjic, May 9, 2015.
12. "ASCO/CAP smjernice za HER2 testiranje u karcinomu dojke: Jesmo li na pravom putu?", Stručni sastanak "Biomarker testiranje u Bosni i Hercegovini", Konjic, May 9, 2015.
13. "Immune check point inhibitori u solidnim tumorima", 1st Sarajevo Winter Oncology Conference: Latest advances in treatment of solid tumors, Jahorina (Sarajevo), 04-06 December 2015
14. „A review of PD-1/PD-L1 in solid tumors in the era of personalized medicine”, Pathology Lecture Series, Department of Pathology, Wayne State University, March 2016. School of Medicine and Affiliated Hospitals, Detroit, Michigan, United States of America
15. „ASCO/CAP smjernice za HER2 testiranje u karcinomu dojke: Da li smo stigli do cilja?“, Stručni sastanak "Biomarker testiranje u BiH: Važnost i odgovornost patologije u eri personalizirane medicine", Teslić, 15-16. april 2016.
16. "Od uzimanja uzorka do molekularnog profiliranja: Izazovi HER2 testiranja". Stručni sastanak "Biomarker testiranje u BiH: Važnost i odgovornost patologije u eri personalizirane medicine", Teslić, 15-16. april 2016.
17. "Novi biomarkeri u eri imunoterapije solidnih tumora", Stručni sastanak "Biomarker testiranje u BiH: Važnost i odgovornost patologije u eri personalizirane medicine", Teslić, 15-16. april 2016.
18. „Apocrine carcinoma of the breast“ (Dr. Zoran Gatalica, Dr. Rebecca Feldman, Dr. Semir Vranić), XXXI International Congress of the IAP and 28th European Congress of Pathology: Breast Pathology: Histology-based prognostic markers besides grade and stage (Session I) & Special types of breast cancers with clinical impact (Session II), Cologne, 25-29 September 2016.
19. „Preanalitička priprema tkiva dojke“, HER2day HER2morrow“, Roche stručni sastanak, 28-29 October, 2016
20. „Određivanje patološkog odgovora nakon završene neoadjuvantne terapije HER2-pozitivnog karcinoma dojke“, Roche stručni sastanak, 28-29 October, 2016
21. „Biomarkers that predict response to the immune check point inhibitors: A brief overview“, "2nd Sarajevo Winter Oncology Conference: Latest advances in treatment of solid tumors", 09-11 December 2016
22. „Molecular pathology: requirements for precision medicine in oncology“, 10-12-2016. „2nd Sarajevo Winter Oncology Conference: Latest advances in treatment of solid tumors“, 09-11 December 2016
23. „Recent advances in molecular pathology of breast cancer“, Jurak Symposium, Zagreb, June 2, 2017
24. „Special types of breast cancer: Molecular genetic features“, 31st Adriatic Society of Pathology International Meeting, Neum, June 30 – July 1, 2017

	<ol style="list-style-type: none"> <li>25. „Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy“, The 3rd Annual Health Cluster Research Symposium, Qatar University, 21-22 April 2018</li> <li>26. “The role of oxidative stress in breast cancer”, 2nd ROS Meeting, Munich, Germany, July 6-8, 2018</li> <li>27. “Predatory journals in pathology: A comprehensive assessment”, IAP 2018, Amman (Jordan), October 2018.</li> <li>28. “The status of predictive biomarkers to immune checkpoint inhibitors in breast cancer”, 8<sup>th</sup> Middle East Cancer Conference, Muscat (Oman), December 2018</li> <li>29. “Recent advances in the molecular pathology of the breast cancer”, 9<sup>th</sup> MEACR Conference, Doha, Qatar, December 2019</li> <li>30. “PD-L1 testing in metastatic triple-negative breast cancer”, Virtual RIME: “Od trostruko negativnog do PD-L1 pozitivnog raka dojke”, June 2020 (Roche Webinar)</li> <li>31. HER2 testing in breast cancer, August 2020 (Roche Webinar)</li> <li>32. Practical Aspects in Implementing a routine pan-TRK IHC Testing: A local pathology perspective in Bosnia and Herzegovina, 11 February 2021 (Roche Training for Practicing Pathologists)</li> <li>33. Scientific publishing for your researchers (SaMED 2021, 28 February 2021)</li> <li>34. Pathology and Precision Medicine, Academy of Sciences and Arts of Bosnia and Herzegovina (ANUBiH), June 10, 2021, link: <a href="https://bbb.anubih.ba/playback/presentation/2.0/playback.html?meetingId=f963959d054143f6cb3bad618956d6b159091a2-1623325683014">https://bbb.anubih.ba/playback/presentation/2.0/playback.html?meetingId=f963959d054143f6cb3bad618956d6b159091a2-1623325683014</a></li> <li>35. Gatalica Zoran, <b>Vranic Semir</b>. Apocrine carcinoma from biomarkers to therapy, 8th Annual Congress of the European Society for Translational Medicine (EUSTM-2021) 26 September, 2021, link: <a href="https://eustm-2021.heysummit.com/talks/apocrine-breast-carcinoma-from-biomarkers-to-therapy/">https://eustm-2021.heysummit.com/talks/apocrine-breast-carcinoma-from-biomarkers-to-therapy/</a></li> <li>36. Gatalica Zoran, <b>Vranic Semir</b>. NTRK gene fusions in cancers and their diagnostics. 11<sup>th</sup> Annual Meeting of the Middle Eastern Association for Cancer Research, November 27, 2021, link: <a href="http://www.qu.edu.qa/conference/meacr">http://www.qu.edu.qa/conference/meacr</a></li> <li>37. <b>Vranic S</b>, Gatalica Z. Molecular and clinical characteristics of apocrine carcinoma of the breast. 28<sup>th</sup> Ljudevit Jurak International Symposium on Comparative Pathology. Zagreb, June 10-11, 2022, link: <a href="https://www.kbcm.hr/2022/06/03/28th-ljudevit-jurak-international-symposium-on-comparative-pathology-2022/">https://www.kbcm.hr/2022/06/03/28th-ljudevit-jurak-international-symposium-on-comparative-pathology-2022/</a>.</li> <li>38. <b>Vranic S</b>. RET fuzije u nemikrocelularnom karcinomu pluća. Roche simpozij “Precizna medicina u srcu onkološke kliničke prakse”, November 11-12, 2022</li> <li>39. <b>Vranic S</b>, Basu G, Gatalica Z. <i>BRAF</i> mutations &amp; other genomic alterations across cancers: An updated review. 12<sup>th</sup> MEACR Annual Meeting, 16-17 December 2022, Casablanca, Morocco</li> <li>40. <b>Vranic S</b>. Indeksiranost i međunarodni utjecaj biomedicinskih časopisa u BiH i region. “Uticaj scientometrije na nauku i akademsku zajednicu”. Round table. Academy of Sciences and Arts of Bosnia and Herzegovina. February 25, 2023.</li> </ol>
<p><b>Hobbies</b></p>	<ul style="list-style-type: none"> <li>• Collecting of Bosnian Traditional Music/Sevdalinka:</li> <li>• Web site/blog: <a href="http://www.sevdalinke.com">http://www.sevdalinke.com</a> (since 1998)</li> <li>• Sevdah Treasure Channel: <a href="https://soundcloud.com/semir-vranic">https://soundcloud.com/semir-vranic</a> (since 2011)</li> <li>• Editor of the edition “From the cultural history of sevdalinka”, BH National Broadcasting Service (BHR1), March 2016 – October 2017 and July 2020-</li> </ul>



- |  |   |
|--|---|
|  | <ul style="list-style-type: none"><li>• Book "Zaboravljeno blago: Stotinu bosanskih narodnih pjesama sa notnim zapisima", Buybook, Zagreb-Sarajevo, 2021 (co-authored with Zanin Berbić), <a href="http://www.buybook.ba/shop/product/4921/zaboravljeno-bлаго">http://www.buybook.ba/shop/product/4921/zaboravljeno-bлаго</a></li></ul> |
|--|---|

## Publications

<u>Citation metric</u>	<u>H-Index (total citations)*</u>	<u>Link</u>
<b>Google Scholar</b>	<b>37</b> (5767 citations)	<a href="https://scholar.google.com/citations?user=9FowakAAAAAJ&amp;hl=en">https://scholar.google.com/citations?user=9FowakAAAAAJ&amp;hl=en</a>
<b>Scopus</b>	<b>29</b> (3471 citations)	<a href="https://www.scopus.com/authid/detail.uri?authorId=6506742049">https://www.scopus.com/authid/detail.uri?authorId=6506742049</a>
<b>Web of Science</b>	<b>27</b> (3210 citations)	<a href="https://publons.com/researcher/1353913/semir-vranic/">https://publons.com/researcher/1353913/semir-vranic/</a>
ORCID: <a href="http://orcid.org/0000-0001-9743-7265">http://orcid.org/0000-0001-9743-7265</a>		

\*As of February 1, 2023

### Peer-reviewed publications (PubMed and Science Citation Indexed)

#### Original studies

1. Bilalović N, **Vranić S**, Hasanagić S, et al. The Bcl-2 protein: A Prognostic indicator strongly related to ER and PR in breast cancer. **Bosn J Basic Med Sci** 2004;4:5-12.
2. Bilalović N, **Vranić S**, Bašić H, Tatarević A, Selak I. Immunohistochemical evaluation of cyclin D1 expression in breast cancer. **Croat Med J** 2005;46:382-88.
3. Silva E, Gatalica Z, Snyder C, **Vranic S**, Lynch JF, Lynch HT. Management of Hereditary Breast-Ovarian Cancer Syndrome. Part II. **Breast J** 2008;14:14-24.
4. **Vranic S**, Caughron SK, Djuricic S, et al. Hamartomas, teratomas and teratocarcino-sarcomas of the head and neck: Report of 3 new cases with clinico-pathologic correlation, cytogenetic analysis, and review of the literature. **BMC Ear Throat Nose Dis** 2008;8:8.
5. **Vranic S**, Tawfik O, Palazzo J, Bilalovic N, Eyzaguirre E, Lee LMJ, Adegboyega P, Hagenkord J, Gatalica Z. EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. **Mod Pathol** 2010;23:644-53.
6. **Vranic S**, Frkovic-Grazio S, Lamovec J, Serdarevic F, Gurjeva O, Palazzo J, Bilalovic N, Lee LMJ, Gatalica Z. Adenoid cystic carcinomas of the breast have low Topo II $\alpha$  expression but frequently over-express EGFR protein without EGFR gene amplification. **Hum Pathol** 2010;41:1617-23.
7. **Vranic S**, Teruya B, Repertinger S, Ulmer P, Hagenkord J, Gatalica Z. Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. **Cancer** 2011; 117:48-53.
8. Zhang XT, Kang LG, Ding L, **Vranic S**, Gatalica Z, Wang ZY. A positive feedback loop of ER- $\alpha$ 36/EGFR promotes malignant growth of ER-negative breast cancer cells. **Oncogene** 2011;30:770-80.
9. **Vranic S**, Gatalica Z, Frkovic-Grazio S, Deng H, Lee LMJ, Gurjeva O, Wang ZY. ER- $\alpha$ 36 a novel isoform of ER- $\alpha$ 66 is commonly over-expressed in apocrine and adenoid cystic carcinoma of the breast. **J Clin Pathol** 2011;64:54-7.
10. **Vranic S**, Gurjeva O, Frkovic-Grazio S, Palazzo J, Tawfik O, Gatalica Z. IMP3, a proposed novel basal phenotype marker, is commonly over-expressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast. **Appl Immunohistochem Mol Morphol** 2011;19:413-16.
11. **Vranic S**, Frkovic-Grazio S, Bilalovic N, Gatalica Z. Angiogenesis in adenoid cystic carcinoma of the breast. **Virchows Arch** 2011;459:377-82.
12. **Vranic S**, Gatalica Z, Wang ZY. Update on molecular profile of the MDA-MB-453 cell line as a model for apocrine carcinoma studies. **Oncol Lett** 2011;2:1131-37.

13. Foco F, Bilalovic N, **Vranic S**, Serdarevic F, Ramovic I, Imamovic E. Peritumoral expression of p53 protein in oral carcinoma. **Coll Antropol** 2012;36(suppl.2):129-132.
14. **Vranic S**, Hes O, Grossmann P, Gatalica Z. Low frequency of HIF-alpha over-expression in germ cell tumors of the testis. **Appl Immunohistochem Mol Morphol** 2013;21:168-72.
15. Dotlic S, Gatalica Z, Wen W, Ghazalpour A, Bridge JA, Mangham C, Babic D, Zekan J, **Vranic S**. Extraskelatal myxoid chondrosarcoma of the vulva with PLAG1 gene activation: Molecular genetic characterization of two cases. **Appl Immunohistochem Mol Morphol** 2014;22:537-42.
16. Zmijanac J, Fabijanovic D, Skrtic A, **Vranic S**, Nikuseva Martic T, Hes O, Serman L. Immunohistochemical expression of Sfrp1 and Sfrp3 proteins in normal and malignant reproductive tissues of rats and humans. **Appl Immunohistochem Mol Morphol** 2014;22:681-7.
17. Serman L, Nikuseva Martic T, **Vranic S**. T-cell factor 1 protein expression in germ cell tumors with trophoblastic differentiation. **Pathol Int** 2014;64:86-7.
18. Peckova K, Vanecek T, Martinek P, Spagnolo D, Kuroda N, Brunelli M, **Vranic S**, Djuricic S, Rotterova P, Daum O, Kokoskova B, Vesela P, Pivovarcikova K, Bauleth K, Dubova M, Kalusova K, Hora M, Michal M, Hes O. Aggressive and non-aggressive translocation t(6;11) renal cell carcinoma: Comparative study of 6 cases and review of the literature. **Ann Diagn Pathol** 2014;18:351-7.
19. Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, Overberg P, Rose I, Basu GD, **Vranic S**, Lynch HT, Von Hoff DD, Hamid O. Programmed cell death (PD-1) and its ligand (PD-L1) expression in common cancers and their correlation with molecular cancer type. **Cancer Epidemiol Biomarkers Prev** 2014;23:2965-70.
20. Gatalica Z, Millis Z, **Vranic S**, Bender R, Basu G, Voss A, Von Hoff D. Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: Analysis of 1806 cases. **Oncotarget** 2014;5(23):12440-7.
21. Millis S, Bryant D, Basu G, Bender R, **Vranic S**, Gatalica Z, Vogelzang N. Molecular theranostic profiling of infiltrating urothelial carcinoma of the bladder and non-bladder origin. **Clin Genitourin Cancer** 2015;13:e37-49.
22. Peckova K, Martinek P, Suster S, Sperga S, Montiel DP, Daum O, Rotterova P, Kalusová K, Hora M, Pivovarcikova K, Rychly B, **Vranic S**, Davidson W, Vodicka J, Michal M, Hes O. Mucinous Spindle and Tubular Renal Cell Carcinoma: Analysis of Chromosomal Aberration Pattern of Low Grade, High Grade and Overlapping Morphologic Variant with Papillary Renal cell Carcinoma. **Ann Diagn Path** 2015;19:226-31.
23. **Vranic S**, Marchiò C, Castellano I, Botta C, Scalzo MS, Bender RP, Payán-Gómez C, Verdun di Cantogno L, Gugliotta P, Tondat F, Francia di Celle P, Mariani S, Gatalica Z, Sapino A. Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast. **Hum Pathol** 2015;46:1350-9.
24. Gatalica Z, Bilalovic N, Palazzo JP, Bender RP, Swensen J, Millis SZ, **Vranic S**, Von Hoff D, Arceci DJ. Disseminated histiocytoses biomarkers beyond BRAFV600E: Frequent expression of PD-L1. **Oncotarget** 2015;6(23):19819-25.
25. Silva E, Gatalica Z, **Vranic S**, Basu G, Sandeep KR, Voss A. Refractory angiosarcoma of the breast with VEGFR2 upregulation successfully treated with Sunitinib: A case report and review of 16 additional cases with a comprehensive molecular profiling. **Breast J** 2015;21:205-7.
26. Millis S, Gatalica Z, Winkler J, **Vranic S**, Kimbrough J, Reddy S, O'Shaughnessy JA. Predictive biomarker profiling of >6,000 breast cancer patients show heterogeneity in TNBC with treatment implications. **Clin Breast Cancer** 2015;15:473-81.

27. Kiss O, Tóké AM, **Vranic S**, Gatalica Z, Szilágyi A, Lippai N, Vass L, Jäckel M, Udvarhelyi N, Szász AM, Kulka J. Posttranscriptional regulators in adenoid cystic carcinomas of the breast and salivary glands. **Virchows Archiv** 2015;467:551-62.
28. Gatalica Z, **Vranic S**, Ghazalpour A, Xiu J, Tolgay Ocal I, McGill J, Bender RP, Disciano E, Schlum A, Sanati S, Palazzo J, Reddy S, Pockaj B. Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast. **Oncotarget** 2016;7:1707-16.
29. Kurtovic-Kozaric A, Hasic A, Radich JP, Bijedic V, Nefic H, Eminovic I, Kurtovic S, Colakovic F, **Vranic S**, Skobic Bovan N. The reality of cancer treatment in a developing country: the effects of the delay of access to imatinib treatment on cytogenetic/ molecular response and survival in patients with chronic myeloid leukemia. **Br J Hematol** 2016;172:420-7.
30. Skenderi F, Ulamec M, **Vranic S**, Bilalovic N, Peckova K, Rotterova P, Kokoskova B, Branzovsky J, Michal M, Hes O. Cystic renal oncocytoma and tubulocystic renal cell carcinoma: Morphologic and immunohistochemical study. **Appl Immunohistochem Mol Morphol** 2016;24:112-9.
31. Lukenda A, Dotlic S, **Vranic S**, Vukojevic N, Saric B, Zarkovic K. Expression and prognostic value of putative cancer stem cell markers CD117 and CD15 in choroidal and ciliary body melanoma. **J Clin Pathol** 2016;69:234-9.
32. Gatalica Z, **Vranic S**, Xiu J, Swensen J, Reddy S. High Microsatellite Instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine. **Fam Cancer** 2016;15:405-12.
33. Ulamec M, Skenderi F, Trpkov K, Kruslin B, **Vranic S**, Bulimbasic S, Trivunic S, Perez-Montiel D, Peckova K, Pivovarcikova K, Ondic O, Daum D, Rotterova P, Dusek M, Hora M, Michal M, Hes O. Solid papillary renal cell carcinoma: Clinicopathologic, morphologic and immunohistochemical analysis of 10 cases and review of the literature. **Ann Diagn Pathol** 2016;23:51-7.
34. Fabijanovic D, Zunic I, Nikuseva Martic T, Skenderi F, Serman L, **Vranic S**. The expression of SFRP1, SFRP3, DVL1 and DVL2 proteins in testicular germ cell tumors. **APMIS** 2016;124:942-9.
35. **Vranic S**, Ghosh N, Kimbrough J, Bilalovic N, Bender R, Arguello D, Veloso Y, Dizdarevic A, Gatalica Z. PD-L1 status in refractory lymphomas. **PLOS One** 2016;11(11):e0166266.
36. Dzinic SH, Bernardo MM, Li X, Fernandez-Valdivia R, Ho YS, Mi QS, Bandyopadhyay S, Lonardo F, **Vranic S**, Oliveira DSM, Bonfil RD, Dyson G, Chen K, Omerovic A, Sheng X, Han X, Wu D, Bi X, Cabaravdic D, Jakupovic U, Wahba M, Sakr W, Sheng S. An essential role of maspin in embryogenesis and tumor suppression. **Cancer Res** 2017;77(4):1-11.
37. Skenderi F, Ulamec M, Vanecek T, Martinek P, Alaghehbandan R, Pane Foix M, Babankova I, Perez Montiel D, Alavarado-Cabrero I, Svajdler M, Dubinsky P, Cempirkova D, Pavlovsky M, **Vranic S**, Daum O, Ondic O, Pivovarcikova K, Michalova K, Hora M, Rotterova P, Stehlikova A, Michal M, Dusek M, Hes O. Warthin-like papillary renal cell carcinoma: Clinicopathologic, morphologic, immunohistochemical and molecular genetic analysis of 11 cases. **Ann Diagn Pathol** 2017;27:48-56.
38. Michal M, Kazakov D, Agaimy A, Hosova M, Michalova K, Grossmann P, Steiner P, Skenderi F, **Vranic S**, Michal M. Whorling Cellular Perineurioma: A previously undescribed variant closely mimicking monophasic fibrous synovial sarcoma. **Ann Diagn Pathol** 2017;27:74-8.
39. Joneja U, **Vranic S**, Swensen J, Feldman R, Chen S, Xiao N, Reddy S, Palazzo J, Gatalica Z. Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of PD-L1. **J Clin Pathol** 2017;70:255–259.
40. **Vranic S**, Feldman R, Gatalica Z. Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers. **Bosn J Basic Med Sci** 2017;17:9-11.
41. Kurtovic-Kozaric A, Kugic A, Hasic A, Beslija S, Ceric T, Pasic A, **Vranic S**, Koprivic D, Iljazovic D, Todorovic Barbuscia J, Ibisevic N, Kurtovic, S. Long-term

- outcome of GIST patients with delayed imatinib therapy. **Eur J Cancer** 2017;78:118-21.
42. Kóvári B, **Vranic S**, Marchio C, Sapino A, Cserni G. The expression of growth hormone releasing hormone (GHRH) and its receptors in breast carcinomas with apocrine differentiation – further evidence of the presence of a GHRH pathway in these tumors. **Hum Pathol** 2017;64:164-70.
  43. Kardum V, Karin V, Glibo M, Skrtic A, Nikuseva Martic T, Ibisevic N, Skenderi F, **Vranic S**, Serman L. Methylation-associated silencing of SFRP1 gene in high-grade serous ovarian carcinomas. **Ann Diagn Pathol** 2017;31:45-9.
  44. Kurtovic-Kozaric A, **Vranic S**, Kurtovic S, Hasic A. Access to targeted cancer treatment modalities in developing world in the era of precision medicine: lessons from Bosnia. **J Global Oncol** 2018;4:1-5.
  45. Zmijanac Partl J, Karin V, Skrtic A, Nikuseva-Martic T, Serman A, Mlinarec J, Curkovic-Perica M, **Vranic S**, Serman L. Comparative analysis of Secreted frizzled-related proteins 1 and 3 (SFRP1/3) and T cell factor 1 (TCF-1) status in normal and pathologic placental development. **J Matern Fetal Neonatal Med** 2018;31:2971-9.
  46. Senarathne W, **Vranic S**, Xiu J, Rose I, Gates P, Gatalica Z. Primary lung non-small cell carcinomas differ in the composition of the immune microenvironment from the carcinomas metastatic to the lungs. **Ann Diagn Pathol** 2018;33:62-8.
  47. Topcagic J, Feldman R, Ghazalpour A, Swensen J, Gatalica Z, **Vranic S**. Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas. **PLOS One** 2018;13(1):e0191244.
  48. Gatalica Z, Xiu I, Swensen J, **Vranic S**. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune check-point blockade therapy. **Eur J Cancer** 2018;94:179-86.
  49. Imamovic D, Bilalovic N, Skenderi F, Beslagic V, Ceric T, Hasanbegovic B, Beslija S, **Vranic S**. A Clinicopathologic Study of Invasive Apocrine Carcinoma of the Breast: A single center experience. **Breast J** 2018;24:1105-8.
  50. Al-Thawadi H, Ghabreau L, Aboukassim T, Yasmeen A, **Vranic S**, Batist G, Al Moustafa AE. Coincidence of Epstein–Barr virus and high-risk human papillomaviruses in cervical cancer of Syrian women. **Front Oncol** 2018;8:250.
  51. Sadek KW, Haik MY, Ashour AA, Aboukassim T, Yasmeen A, **Vranic S**, Zeidan A, Al Moustafa AE. Water-pipe smoking promotes epithelial-mesenchymal transition and invasion of human breast cancer cells via ERK1/ERK2 pathways. **Cancer Cell Int** 2018;18:180.
  52. Gatalica Z, Xiu J, Swensen J, **Vranic S**. Molecular characterization of cancers with NTRK gene fusions. **Mod Pathol** 2019;32:147-53.
  53. **Vranic S**, Palazzo J, Swensen J, Xiu J, Florento E, Gatalica Z. Theranostic molecular profiling of pleomorphic ductal carcinoma of the breast. **Breast J** 2019;25(1):175-6.
  54. **Vranic S**, Palazzo J, Sanati S, Florento E, Contreras E, Xiu J, Swensen J, Gatalica Z. Novel predictive biomarkers of targeted treatment for patients with neuroendocrine carcinoma of the breast. **Clin Breast Cancer** 2019;19:131-6.
  55. Terlević R, Perić Balja M, Tomas D, Krušlin B, **Vranic S**, Skenderi F, Demirović A. Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer. **Ann Diagn Pathol** 2019;38:62-6.
  56. Khalil AA, Al-Qahdi SS, Alzohari N, Alsaid AY, Ashour AA, Aboukassim A, **Vranic S**, Al Moustafa AE. Teucrium Polium Plant Extract Provokes Substantial Cytotoxicity at the Early Stage of Embryonic Development. **Bosn J Basic Med Sci** 2019;19(1):67-71.

57. Dzinic SH, Mahdi Z, Bernardo MM, **Vranic S**, Beydoun H, Nahra N, Alijagic A, Harajli D, Pang A, Saliganan DM, Rahman AM, Latchmansingh KA, Raval K, Skenderi F, Hasanbegovic B, Dyson G, Beydoun R, Sheng S. Maspin Differential Expression Pattern as a Marker for Targeted Screening of Gastroesophageal Junction Adenocarcinoma. **PLoS One** 2019;14:e0215089.
58. **Vranic S**, Senarathne W, Stafford P, Poorman K, Pockaj B, Gatalica Z. Biomarkers of targeted therapy and immuno-oncology in cancers metastatic to the breast. **Appl Immunohistochem Mol Morphol** 2020;28:661-8.
59. Zvizdic Z, Islamovic B, Milisic E, Jonuzi A, Hadzimehmedagic A, **Vranic S**. Changing trends in the referral and timing of treatment for congenital cryptorchidism: A single-center experience from Bosnia and Herzegovina. **J Pediatr Surg** 2020;55:1965-8.
60. Mardekian S, **Vranic S**, Swensen J, Senarathne J, Feldman R, Gatalica Z. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling. **Cancer Med** 2019;8(17):7322-7329. doi: 10.1002/cam4.2602.
61. AlAhmad YFM, Abdelhafez IHE, Cyprian FS, Skenderi F, Akhtar S, **Vranic S**. A critical appraisal of predatory journals in pathology. **J Clin Pathol** 2020;73(1):58-60.
62. Karin-Kujundzic V, Kardum V, Sola IM, Paic F, Skrtic A, Skenderi F, Serman A, Nikuseva-Martic N, **Vranic S**, Serman L. Dishevelled family proteins in serous ovarian carcinomas: A clinicopathologic and molecular study. **APMIS** 2020;128(3):201-210.
63. Gatalica Z, **Vranic S**, Krušlin B, Poorman K, Stafford P, Kacerovska D, Senarathne W, Florento E, Contreras E, Leary A, April C, In GK. Biomarkers of targeted therapy in Extramammary and mammary Paget Disease. **Cancer Med** 2020;9:1441-50.
64. Zvizdic Z, Pasic Sefic I, Džananovic A, Rustempasic N, Milisic E, Jonuzi A, **Vranic S**. Bowel dilatation on initial plane abdominal radiography may help to assess the severity of necrotizing enterocolitis in preterm infants. **Children (Basel)** 2020;7(2):9.
65. Malki MI, Gupta I, Fernandes Q, Aboukassim T, Yasmeen A, **Vranic S**, Al Moustafa AE, Al-Thawadi HA. Co-presence of Epstein–Barr virus and high-risk human papillomaviruses in colorectal cancers in Syria. **Hum Vaccin Immunother** 2020;16(10):240-7, doi; 10.1080/21645515.2020.1726680.
66. **Vranic S**, Stafford P, Palazzo J, Skenderi F, Swensen J, Xiu J, Spetzler D, Gatalica Z. Molecular profiling of the metaplastic spindle cell carcinoma of the breast reveals potentially targetable biomarkers. **Clin Breast Cancer** 2020;20:326-31.e1. doi: 10.1016/j.clbc.2020.02.008.
67. Kalhor N, Lindholm K, Brunnstrom H, Langman G, Jang, Se J, Spagnolo D, Chai S, Laycock A, Falconieri G, Pizzolitto S, de Pellegrin A, Medeiros F, Edmunds L, Catarino A, Cunha F, Ro J, Pina-Oviedo S, Torrealba J, Coppola D, Petersson F, Oon M, Elmberger G, Cajal S, Sansano-Valero I, Dalurzo L, Soares F, Campos A, **Vranic S**, Skenderi F, Correa A, Sepesi B, Rice D, Merhan R, Walsh G, Moran C. Predictive clinical and histopathological factors in neuroendocrine neoplasms of the lung (typical and atypical carcinoid). A clinicopathological analysis of 783 cases. **Hum Pathol** 2020;98:98-109. DOI: 10.1016/j.humpath.2020.02.005
68. Gupta I, Jabeen A, Smatti MK, Al-Thawadi H, Nasrallah GK, Sultan AA, **Vranic S**, Al Moustafa AE. Co-Prevalence of Human Papillomaviruses (HPV) and Epstein Barr virus (EBV) in Healthy Blood Donors from diverse Nationalities in Qatar. **Cancer Cell Int** 2020;20:107.
69. Skenderi F, Palazzo J, Swensen J, Feldman R, Contreras E, Florento E, Gatalica Z, **Vranic S**. Novel Targetable Biomarkers in Clear Cell Carcinoma of the Breast Uncovered by Molecular Profiling: A study of nine cases. **Breast J** 2020;26:1781-3, <http://dx.doi.org/10.1111/tbj.13842>
70. Gupta I, Ghabreau L, Al-Thawadi H, Yasmeen A, **Vranic S**, Al Moustafa AE, Malki MI. Co-Incidence of Human Papillomaviruses and Epstein–Barr Virus is Associated with High to Intermediate Tumor grade in Human Head and Neck Cancer in Syria. **Front Oncol** 2020;10:1016, <https://doi.org/10.3389/fonc.2020.01016>

71. Ashour A, Alhussain H, Bin Rashid U, Abughazzah L, Gupta I, **Vranic S**, Al Moustafa AE. E-cigarette liquid provokes a significant embryotoxicity and angiogenesis inhibition of the normal development. **Toxics (Basel)** 2020;8(2):38. doi:10.3390/toxics8020038
72. Gupta I, AlFarsi H, Jabeen A, Skenderi F, Al-Thawadi H, AlAhmad YM, Al Moustafa AE, **Vranic S**. High-risk Human Papillomaviruses and Epstein-Barr virus in Colorectal Cancer and their Association with Clinicopathological Status. **Pathogens** 2020;9(6):452. <https://doi.org/10.3390/pathogens9060452>
73. Jabeen A, Gupta I, Skenderi F, Sharma A, Al-Thawadi H, **Vranic S**, Al Moustafa AE. Co-Incidence of Epstein–Barr Virus (EBV) and Human Papillomaviruses (HPVs) in Head and Neck Carcinomas from the Bosnian population. **Cancer Cell Int** 2020;20:361, <https://doi.org/10.1186/s12935-020-01348-y>
74. Zvizdic Z, Kovacevic A, Milisic E, Jonuzi A, **Vranic S**. Clinical course and short-term outcome of postsplenectomy reactive thrombocytosis in children without myeloproliferative disorders: A single institutional experience from a developing country. **PLOS One** 2020;15(8): e0237016. <https://doi.org/10.1371/journal.pone.0237016>
75. Jabeen A, Sharma A, Gupta I, Kheraldine H, **Vranic S**, Al Moustafa AE, Al Farsi H. Elaeagnus Angustifolia plant extract inhibits epithelial-mesenchymal transition and induces apoptosis via HER2 inactivation and JNK pathway in HER2-positive Breast Cancer Cells. **Molecules (Basel)** 2020;25(18):4240, <https://doi.org/10.3390/molecules25184240>.
76. López-Ozuna VM, Gupta I, Chen Kiow RL, Matanes E, Yasmeen A, **Vranic S**, Al Moustafa AE, Al Farsi HF. Water-pipe smoking exposure deregulates a set of genes and molecular pathways associated with human head and neck cancer development and prognosis. **Toxics (Basel)** 2020;8(3):73, <https://doi.org/10.3390/toxics8030073>
77. Gupta I, Jabeen A, Al-Sarraf R, Farghaly HC, **Vranic S**, Sultan AA, Al Moustafa AE, Al-Thawadi H. The co-presence of high-risk human papillomaviruses and Epstein-Barr virus is linked with tumor grade and stage in Qatari women with breast cancer. **Hum Vaccin Immunother** 2021;17(4):982-9, doi: 10.1080/21645515.2020.1802977.
78. Zvizdic Z, Aganovic A, Milisic E, Jonuzi A, Zvizdic D, **Vranic S**. Duration of symptoms is the only predictor of testicular salvage following testicular torsion in children: A case-control study. **Am J Emerg Med** 2021;41:197-200, <https://doi.org/10.1016/j.ajem.2020.11.023> .
79. Cimic A, **Vranic S**, Arguello D, Contreras E, Gatalica Z, Swensen J. Molecular profiling reveals novel targetable biomarkers in neuroendocrine carcinoma of the cervix. **Appl Immunohistochem Mol Morphol** 2021;29:299-304, doi: 10.1097/PAI.0000000000000884.
80. Sola IM, Serman A, Karin-Kujundzic V, Paic F, Skrtic A, Slatina P, Kakarigi L, **Vranic S**, Serman L. Dishevelled family proteins expression in IUGR placentas. **Bosn J Basic Med Sci** 2021;21:447-53, <https://doi.org/10.17305/bjbms.2020.5422>
81. Kruslin B, Gatalica Z, Hes O, Skenderi F, Miettinen M, **Vranic S**, Contreras E, Xiu J, Elis M, Florento E, Swensen J. TERT gene fusions characterize a subset of metastatic Leydig cell tumors. **Clin Genitourinary Cancer** 2021;19(4):333-8, <https://doi.org/10.1016/j.clgc.2021.02.002>
82. Zvizdic Z, Milisic E, Jonuzi A, Terzic S, Zvizdic D, **Vranic S**. The effects of ranitidine on the risk of necrotizing enterocolitis in preterm infants: A case-control study. **Acta Medica (Hradec Králové)** 2021; 64(1): 8–14, <https://doi.org/10.14712/18059694.2021.2>
83. Gupta I, Jabeen A, **Vranic S**, Al Moustafa AE, Al-Thawadi H. Oncoproteins of high-risk HPV and EBV cooperate to enhance cell motility and invasion of human breast cancer cells via Erk1/Erk2 and Wnt/beta-catenin signaling pathways. **Front Oncol** 2021;11:630408. doi: 10.3389/fonc.2021.630408

84. Gupta I, López Ozuna V, Matanes E, Malki M, Yasmeen A, **Vranic S**, Al Moustafa AE, Al-Farsi H. Identification of a set of genes associated with breast cancer development and prognosis induced by water-pipe smoking. **Clinical Cancer Investigation J** 2021;10(6):318-30, DOI: 10.4103/ccij.ccij\_109\_21.
85. Nagi K, Gupta I, Jabeen A, Aboukassim T, Yasmeen A, Batist G, **Vranic S**, Al Moustafa AE. High-risk human papillomaviruses and Epstein-Barr virus in breast cancer in Lebanese women and their association with tumor type and grade: A molecular and tissue microarray study. **Cancer Cell Int** 2021; 21(1):308, doi: 10.1186/s12935-021-02009-4.
86. Zvizdic Z, Duric Golos A, Milisic E, Jonuzi A, Zvizdic D, **Vranic S**. The predictors of perforated appendicitis in the pediatric emergency department: A retrospective cohort study. **Am J Emerg Med** 2021;49:249-52, <https://doi.org/10.1016/j.ajem.2021.06.028>.
87. Nagi K, Gupta I, Jurdi N, Yasmeen A, **Vranic S**, Batist G, Al Moustafa AE. Co-Presence of High-risk Human Papillomaviruses and Epstein-Barr virus in colorectal cancer: a tissue microarray and molecular study from Lebanon. **Int J Mol Sci** 2021;22(15):1818, <https://doi.org/10.3390/ijms22158118>
88. Sharma S, Moinuddin Z, Summers A, Shenoy M, Plant N, **Vranić S**, Prytula A, Zvizdic Z, Karava V, Printza N, Vlot J, van Dellen D, Augustine T. Surgical management of Encapsulating Peritoneal Sclerosis (EPS) in children – case series from an international referral centre. **Pediatr Nephrol**. 2022;37(3):643-50. doi: 10.1007/s00467-021-05243-0.
89. Gupta I, Ulamec M, Peric-Balja M, Ramic S, Al Moustafa AE, **Vranic S**, Al-Farsi HF. The Presence of Multiple Oncoviruses in Triple-Negative Breast Cancer. **Hum Vaccin Immunother**. 2021 Oct 8:1-10. doi: 10.1080/21645515.2021.1975452.
90. Bonfil RD, Chen W, **Vranić S**, Sohail A, Oliveira DSM, Shi D, Jang H, Kim HR, Richter H, Prunotto M, Fridman R. Discoidin domain receptor 1 (DDR1) Expression and Prostate Cancer Aggressiveness. **Cancer Cell Int** 2021;21(1):507, doi: 10.1186/s12935-021-02206-1.
91. Mahmoud NN, Zakaria ZZ, Kheraldine H, Gupta I, **Vranic S**, Al Moustafa AE. The Effect of Surface-Modified Gold Nanorods on the Early Stage of Embryonic Development and Angiogenesis: Insight into the Molecular Pathways. **Int J Mol Sci** 2021;22(20):11036, <https://doi.org/10.3390/ijms222011036>
92. Zvizdic Z, Halimic T, Milisic E, Jonuzi A, Alajbegovic Halimic J, **Vranic S**. The epidemiological and clinical features of infantile hypertrophic pyloric stenosis: A hospital-based study from Bosnia and Herzegovina. **Asian J Surg** 2022;45:1694-7, <https://doi.org/10.1016/j.asjsur.2021.10.012>
93. Cimic A, Smithgall MC, Khoury-Collado F, Liu-Jarin X, **Vranic S**. Value of Additional Sections: Tissue Handling of Small Biopsies in Detecting Squamous Dysplasia of the Uterine Cervix. **Ann Diagn Pathol** 2022;56:151872, <https://doi.org/10.1016/j.anndiagpath.2021.151872> .
94. Zvizdic Z, Aganovic A, Milisic E, Jonuzi A, Zvizdic D, **Vranic S**. Comparison of demographic and clinical characteristics in distinguishing testicular torsion from torsion of the appendix testis. **Asian J Urol** 2022 April 11 Advanced Online, <https://doi.org/10.1016/j.ajur.2022.04.001>.
95. Skenderi F, Alahmad MAM, Tahirovic E, Alahmad YM, Gatalica Z, **Vranic S**. HER2-positive Apocrine Carcinoma of the Breast: A population-based Analysis of Treatment and Outcome. **Breast Cancer Res Treat**. 2022;193:523-33, doi: 10.1007/s10549-022-06578-4.
96. Gupta I, Al-Sarraf R, Al-Farghaly H, **Vranic S**, Sultan AA, Al-Thawadi H, Al-Farsi HF, Al Moustafa AE. Incidence of HPVs, EBV and MMTV-like Virus in Breast Cancer in Qatar. **Intervirolgy**. 2022;65:188-94, doi: 10.1159/000525277.
97. Karin-Kujundzic V, Covarrubias-Pinto A, Skrtic A, **Vranic S**, Serman L. PTCH1 expression in serous ovarian carcinomas: A comprehensive immunohistochemical and molecular study. **Int J Oncol**



- 2022;61(6):145, doi: 10.3892/ijo.2022.5435
98. Jonuzi A, Zvizdic Z, Milisic E, Kulovac B, Mesic A, **Vranic S**. Assessment of postoperative cosmetic outcomes of distal form hypospadias repair with the Hypospadias Objective Scoring Evaluation (HOSE). **Med Glas** 2022;19(2):212-17, doi: 10.17392/1482-22.
  99. Gatalica Z, Stafford S, **Vranic S**. Alpha-methylacyl-CoA Racemase (AMACR) Protein is Upregulated in Early Proliferative Lesions of the Breast Irrespective of Apocrine Differentiation. **Hum Pathol** 2022;129:40-6, doi: 10.1016/j.humpath.2022.08.002.
  100. Sola IM, Karin-Kujundzic V, Paic F, Lijovic L, Serman N, Skrtic A, Kuna K, **Vranic S**, Serman L. The status of WNT5A,  $\beta$ -catenin and SUFU proteins in placentas with intrauterine growth restriction (IUGR). **Mol Medicine Reports** 2023;27:28, <https://doi.org/10.3892/mmr.2022.12914>
  101. Padmanabhan R, Kheraldine H, Meskin N, Hamad A, **Vranic S**, Al Moustafa AE. Quantification of the growth suppression of HER2+ breast cancer colonies under the effect of trastuzumab and PD-1/PD-L1 inhibitor. **Front Oncol** 2022;12:977664, <https://doi.org/10.3389/fonc.2022.977664>
  102. Zvizdic Z, Becirovic N, Milisic E, Jonuzi A, Terzic S, **Vranic S**. The Prevalence and Clinical Characteristics of Selected Surgically Correctable Major Congenital Anomalies at the Largest Bosnian Tertiary Referral Center: A Five-year Hospital-based Study. **Medicine (Baltimore)** 2022; 101(48):e32148. doi: 10.1097/MD.00000000000032148.
  103. Zvizdic Z, Jonuzi A, Milisic E, Hadzimehmedagic A, **Vranic S**. Clinicopathologic Characteristics of Sacrococcygeal Teratoma: A Case Series from Bosnia and Herzegovina. **Turkish Archives of Pediatrics** 2023, in press.

## **Reviews**

1. Bilalović N, **Vranić S**, Serdarević F, Fočo F. The role of the stroma in carcinogenesis. **Bosn J Basic Med Sci** 2006;6:33-8.
2. **Vranic S**, Bender R, Palazzo J, Gatalica. Z. A review of adenoid cystic carcinoma of the breast with emphasis on its molecular and genetic characteristics. **Hum Pathol** 2013; 44:301-9.
3. **Vranic S**, Schmitt F, Sapino A, Costa JL, Reddy S, Castro M, Gatalica Z. Apocrine carcinoma of the breast: A comprehensive review. **Histol Histopathol** 2013;28:1393-1409.
4. Serman L, Nikuseva Martic T, Serman A, **Vranic S**. Epigenetic changes of the Wnt signaling pathway in cancer – mini review. **Bosn J Basic Med Sci** 2014;14:191-4.
5. Skenderi F, **Vranic S**, Damjanov I. Programmed cell death in diagnostic histopathology. **Int J Dev Biol** 2015;59:149-58.
6. Damjanov I, **Vranic S**, Skenderi F. Does everything a surgeon takes out have to be seen by a pathologist? A review of the current pathology practice. **Virchows Arch** 2016;468:69-74.
7. Damjanov I, Skenderi F, **Vranic S**. Mammary Analogue Secretory Carcinoma (MASC) of the salivary gland: A new tumor entity. **Bosn J Basic Med Sci** 2016;16:237-8.
8. Skoda AM, Simovic D, Karin V, Kardum V, **Vranic S**, Serman S. The role of the Hedgehog signaling pathway in cancer. **Bosn J Basic Med Sci** 2018;18(1):8-21.
9. **Vranic S**. Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: A comment on recent advances. **Bosn J Basic Med Sci** 2017;17:274-5.
10. Imamovic D, **Vranic S**. Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4: A new avenue to enhance the therapeutic benefits of immune check point inhibitors. **Ann Transl Med** 2017;5:467.
11. **Vranic S**, Cyprian FS, Akhtar S, Al Moustafa AE. The role of Epstein-Barr virus (EBV) in cervical cancer: A brief update. **Front Oncol** 2018;8:113.

12. Cyprian FS, Al-Farsi HF, **Vranic S**, Akhtar S, Al Moustafa AE. Epstein-Barr virus and human papillomaviruses interactions and their roles in the initiation of EMT and cancer progression: A brief review. **Front Oncol** 2018;8:111.
13. Akhtar S, **Vranic S**, Cyprian FS, Al Moustafa AE. Epstein-Barr Virus in Gliomas: Cause, Association or Artefact? **Front Oncol** 2018;8:123.
14. Willenbacher W, Seeber A, Steiner N, Willenbacher E, Gatalica Z, Swensen J, Kimbrough J, **Vranic S**. Is the time ready for molecular profiling in relapsed and refractory multiple myeloma patients? A comprehensive literature review. **Int J Mol Sci** 2018;19(7):2087.
15. Bedri S, Sultan AA, Alkhalaf M, Al Moustafa AE, **Vranic S**. Status of Epstein-Barr virus in colorectal cancer: A brief review. **Human Vaccines & Immunotherapeutics** 2019;15:603-10.
16. Gupta IR, Sareyeldin RM, Al-Hashimi I, Al-Thawadi H, **Vranic S**, Al Moustafa AE. Progression of the triple negative breast cancer profile from gene to microRNA: an overview. **Cancers** 2019;11(3):363.
17. Cyprian FS, Akhtar S, Gatalica Z, Vranic S. Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer. **Bosn J Basic Med Sci** 2019;19(3):227-33.
18. Sareyeldin RM, Gupta I, Al-Hashimi I, Al-Thawadi HA, Al Farsi H, **Vranic S**, Al Moustafa AE. Gene expression profiling and miRNA status in HER2-positive breast cancer: A concise review. **Cancers** 2019;11(5):646.
19. Gatalica Z, Feldman R, **Vranic S**, Spetzler D. Immunohistochemistry-enabled Precision Medicine. **Cancer Treat Res** 2019;178:111-135. doi: 10.1007/978-3-030-16391-4\_4.
20. Karin-Kujundzic V, Sola IM, Predavec N, Potkonjak A, Somen E, Mioc P, Serman A, **Vranic S**, Serman L. Novel Epigenetic Biomarkers in Pregnancy-Related Disorders and Cancers. **Cells** 2019; 8(11):1459
21. **Vranic S**, Cyprian FS, Gatalica Z, Palazzo J. PD-L1 status in breast cancer: Current view and perspectives. **Semin Cancer Biol** 2021;72:146-54, <https://doi.org/10.1016/j.semcancer.2019.12.003>
22. Padmanabhan R, Kheraldine HS, Meskin N, **Vranic S**, Al Moustafa AE. Crosstalk between HER2 and PD-1/PD-L1 in breast cancer: from clinical applications to mathematical models. **Cancers (Basel)** 2020;12:636. <https://doi.org/10.3390/cancers12030636>
23. **Vranic S**, Skenderi F, Beslagic V, Gatalica Z. Glycogen-rich clear cell carcinoma of the breast: A concise review. **Appl Immunohistochem Mol Morphol** 2020;28:655-60, doi: 10.1097/PAI.0000000000000850.
24. Fernandes Q, Gupta I, **Vranic S**, Al Moustafa AE. Human papillomaviruses and Epstein-Barr virus interaction in human colorectal cancers: A concise review. **Pathogens** 2020;9(4):300, <https://doi.org/10.3390/pathogens9040300>
25. Allouch S, Malki A, Allouch A, Gupta I, **Vranic S**, Al Moustafa AE. Oncoproteins of High-Risk HPVs and PD-1/PD-L1 Crosstalk in Cervical Cancer: Recent Evidence and Future Directions. **Front Oncol** 2020;10:914, <https://doi.org/10.3389/fonc.2020.00914>.
26. Bešlija S, Gojković Z, Cerić T, Mekić Abazović A, Marijanović I, **Vranic S**, Mustedanagić-Mujanović J, et al. 2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina. **Bosn J Basic Med Sci** 2020 Epub Ahead Print May16 <https://doi.org/10.17305/bjbms.2020.4846>
27. **Vranic S**, Beslija S, Gatalica Z. Targeting HER2 expression in cancer: New drugs and new indications. **Bosn J Basic Med Sci** 2021;21:1-4, <https://doi.org/10.17305/bjbms.2020.4908>
28. Glibo M, Serman A, Karin-Kujundzic V, Bekavac I, Miskovic B, **Vranic S**, Serman L. The role of glycogen synthase kinase 3 (GSK3) in cancer with emphasis on ovarian cancer development and

- progression: A comprehensive review. **Bosn J Basic Med Sci** 2021;21:5-18, <https://dx.doi.org/10.17305/bjbms.2020.5036>.
29. Gupta I, Rizeq B, Elkord E, **Vranic S**, Al Moustafa AE. SARS-CoV-2 infection and lung cancer: Prognosis and therapeutic modalities. **Cancers (Basel)** 2020;12(8):2186, <https://doi.org/10.3390/cancers12082186>.
  30. Gupta I, Rizeq B, **Vranic S**, Al Moustafa AE; Al Farsi H. Circulating MiRNAs in ER-negative Breast Cancer: Potential biomarkers & therapeutic targets. **Int J Mol Sci** 2020;21(18):6750, <https://doi.org/10.3390/ijms21186750>
  31. Allouch S, Gupta I, Malik I, Al Farsi HF, **Vranic S**, Al Moustafa AE. Breast cancer and pregnancy: A marked propensity to triple-negative phenotype. **Front Oncol** 2020;10:580345, doi: 10.3389/fonc.2020.580345
  32. Malki A, ElRuz RA, Gupta I, Allouch A, **Vranic S**, Al Moustafa AE. Molecular mechanisms of colon cancer progression and metastasis: Recent insights and advancements. **Int J Mol Sci** 2021;22(1):130, <https://doi.org/10.3390/ijms22010130>
  33. Vranic S, **Gatalica Z**. The role of pathology in the era of personalized (precision) medicine: A brief review. **Acta Medica Academica** 2021;50(1):47-57.
  34. Gupta I, Sohail M, **Vranic S**, Al-Asmakh M, Al Moustafa AE. SARS-CoV-2 Infection and Smoking: What is the association? A concise review. **Computational and Structural Biotechnology J** 2021;19:1654-60, <https://doi.org/10.1016/j.csbj.2021.03.023>
  35. **Vranic S**, Gatalica Z. Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers. **Bosn J Basic Med Sci** 2022;22:14-21, doi: 10.17305/bjbms.2021.6100.
  36. Luo W, Stevens T, Stafford P, Miettinen M, Gatalica Z, **Vranic S**. NUTM1-Rearranged Neoplasms: A Heterogeneous Group of Primitive Tumors with Expanding Spectrum of Histology and Molecular Alterations: An Updated Review. **Curr Oncol** 2021;28(6):4485-4503; <https://doi.org/10.3390/curroncol28060381>
  37. Gupta I, **Vranic S**, Al Moustafa AE. Fascin in Gynecological Cancers: An emerging biomarker and therapeutic target. **Cancers** 2021;13:5760. <https://doi.org/10.3390/cancers13225760>
  38. Ouda AM, Elsabagh AA, Elmakaty IM, Gupta I, **Vranic S**, Al Moustafa AE. HPVs and Recurrent Respiratory Papillomatosis: A Brief Review. **Life (Basel)** 2021;11(11):1279, <http://dx.doi.org/10.3390/life11111279>
  39. **Vranic S**, Gatalica Z. An update on the molecular and clinical characteristics of apocrine carcinoma of the breast. **Clinical Breast Cancer** 2022;22(4):e576-e585, <https://doi.org/10.1016/j.clbc.2021.12.009> .
  40. Serman N, **Vranic S**, Serman L, Glibo M, Mokos Bukvic Z. Genetic risk factors in melanoma etiopathogenesis and the role of genetic counseling: A concise review. **Bosn J Basic Med Sci** 2022;22:673-82, <https://doi.org/10.17305/bjbms.2021.7399>
  41. Sheikh E, Tran T, **Vranić S**, Levy A, Bonfil RD. Role and Significance of c-KIT Receptor Tyrosine Kinase in Cancer: A Review. **Bosn J Basic Med Sci** 2022;22:683-698, <https://doi.org/10.17305/bjbms.2021.7399>
  42. Gupta I, Pedersen S, **Vranic S**, Al Moustafa AE. Implications of Gut Microbiota on Epithelial-Mesenchymal Transition and Cancer Progression. **Cancers** 2022, 14(12), 2964; <https://doi.org/10.3390/cancers14122964>
  43. **Vranic S**, Gatalica Z. The predictive role of PD-L1 immunohistochemistry in Immuno-Oncology. **Biomol Biomed** 2023;23(1):15-25, <https://doi.org/10.17305/bjbms.2022.7953>.

44. Ajkunic A, Skenderi F, Shaker N, Akhtar S, Lamovec J, Gatalica Z, **Vranic S**. Acinic Cell Carcinoma of the Breast: A Comprehensive Review. **Breast** 2022;66: 208-16, <https://doi.org/10.1016/j.breast.2022.10.012>
45. Fernandes Q, Allouch S, Gupta I, **Vranic S**, Al-Farsi H, Al Moustafa AE. Human papillomaviruses-related cancers: An Update on the Presence and Prevention Strategies in the Middle East and North African (MENA) Regions. **Pathogens** 2022; 11(11):1380, <https://doi.org/10.3390/pathogens11111380>
46. **Vranic S**, Basu G, Hall DW, Gatalica Z. Tumor-type agnostic, targeted therapies. BRAF inhibitors join the group. **Acta Medica Academica** 2022;51(3): <https://www.ama.ba/upcoming/66-22-Acta%20Medica%20Academica%203-2022%20Semir%20Vranic.pdf>

### Case reports/comments/letters to editor/editorials

1. **Vranić S**, Kapur L, Fočo F, Bilalović N, Hainaut P. The first case of Li-Fraumeni syndrome in Bosnia and Herzegovina: Case report. **Pathologica** 2006;98:156-59.
2. **Vranić S**, Bilalović N, Lee LMJ, Krušlin B, Lilleberg S, Gatalica Z. PIK3CA and PTEN mutations in adenoid cystic carcinoma of the breast metastatic to kidney. **Hum Pathol** 2007;38:1425-31.
3. Gatalica Z, Lilleberg SL, **Vranic S**, Eyzaguirre E, Orihuela E, Velagaleti G. Novel intronic germ-line FLCN gene mutation in a patient with multiple ipsilateral renal neoplasms. **Hum Pathol** 2009;40:1813-19.
4. Dotlic S, **Vranic S**, Jakovljevic G, Ilic I, Kardum-Paro MM, Dojcinov SD. Neonatal hyperimmune T-cell reaction mimicking T-cell non-Hodgkin lymphoma following BCG and Hepatitis B co-vaccination. **Virchows Archiv** 2012;461:601-5.
5. Skenderi F, Krakonja F, **Vranic S**. Infarcted fibroadenoma of the breast: Report of two cases with review of the literature. **Diagn Pathol** 2013;8(1):38.
6. Marusic Z, Kos M, Labinec-Peteh L, **Vranic S**, Luzar B. Cystic fibroepithelioma of Pinkus: Report of two cases and review of cystic changes in classical fibroepithelioma of Pinkus. **Bosn J Basic Med Sci** 2014;14:205-8.
7. Redzepagic J, Skenderi F, Bajrovic J, Beslagic V, Ibisevic N, **Vranic**. Low-grade malignant peripheral nerve sheath tumor of the breast: A report of the first case and literature review. **APMIS** 2016;124:428-30.
8. Skenderi F, Chikha A, Ibisevic N, Tatarevic-Suko A, Kantardzic N, **Vranic S**. Skeletal muscle metastases of the cervical carcinoma: Report of two cases with literature review. **Int J Gynecol Pathol** 2017;36:95-100.
9. Zvizdic Z, Milisic E, Chikha A, Sefic I, Džananovic A, **Vranic S**. Encysted Hydrocele of the Canal of Nuck in an 11-Month-Old-Child with a Past History of Duodenal Atresia and Arnold-Chiari Malformation: A case report. **Medicine (Baltimore)** 2019; 98(4):e14232.
10. Zvizdic Z, Jonuzi A, Djuran A, Mesic A, **Vranic S**. Gastric Necrosis and Perforation Following Massive Acute Gastric Dilatation in an Adolescent Girl: A Rare Cause of Acute Abdomen. **Front Surg** 2019;6:3.
11. Imamovic D, Bilalovic N, Skenderi F, Beslagic V, Ceric T, Hasanbegovic B, Beslija S, **Vranic S**. Reply Letter to the Editor. **Breast J** 2019;25(3):569
12. Zvizdic Z, Haxhija E, Chikha A, **Vranic S**, Milisic E, Jonuzi A. Laparoscopic extirpation of adrenal gland ganglioneuroma incidentally diagnosed after evaluation for alopecia areata patchy in an adolescent boy. **Med Principles Pract** 2019;28(5):485-489.
13. **Vranic S**. A comment on the paper on metaplastic carcinoma of the breast. **Breast J** 2019; 25(6):1330-1.

14. Cubro H, Cengic V, Burina N, Kravic Z, Beciragic E, **Vranic S**. Appendiceal Mucocele Presenting as an Exacerbated Chronic Tubo-ovarian Abscess: A Case Report and Comprehensive Literature Review. **Medicine (Baltimore)** 2019 Sep;98(39):e17149.
15. Zvizdic Z, Pasic-Sefic I, **Vranic S**. Acute perforated appendicitis after blunt abdominal trauma from horse hoof kick: A case report and literature review. **Am J Emerg Med** 2020;38:408.e1-408.e2
16. **Vranic S**. Letter to Editor: Apocrine carcinoma is the fact. Comment on the recent paper entitled "Invasive apocrine carcinoma of the breast: Myth or fact?" by Gurrado et al (Breast J. 2019;26(3):545-546.). **Breast J** 2020;26(4):838. <https://doi.org/10.1111/tbj.13681>
17. Zvizdic Z, Popovic N, Milisic E, Mesic E, **Vranic S**. Apple-peel jejunal atresia associated with multiple ileal atresias in a preterm newborn: A rare congenital anomaly. **J Paediatr Child Health** 2020;56:1814-6, doi: 10.1111/jpc.14793.
18. Zvizdic Z, Milisic E, **Vranic S**. Penile degloving and dorsal dartos flap rotation surgery in the management of severe isolated penile torsion in a 6-year-old boy. **Acta Medica (Hradec Králové)** 2020;63(1):52-4.
19. Zvizdic Z, Milisic E, Skenderi F, Sefic Pasic I, **Vranic S**. A free terminal ileal perforation as the presenting sign of Crohn's disease in an adolescent female. **Central Eur J Paediatrics** 2020;16(1):83-4. <https://doi.org/10.5457/p2005-114.259>
20. Zvizdic Z, Bukvic M, Murtezic S, Skenderi F, **Vranic S**. Giant paratubal serous cystadenoma in an adolescent female: Case report and literature review. **J Pediatric Adolescent Gynecol** 2020;33:438-40, <https://doi.org/10.1016/j.jpag.2020.03.010>.
21. Zvizdic Z, Rustempasic N, Sefic Pasic I, Skenderi F, **Vranic S**. A case of extra-adrenal retroperitoneal ganglioneuroma enclosing large blood vessels in a 9-year-old female: A report of rare case and literature review. **Central Eur J Paediatr** 2020;16(2):141-5, [https://cejpaediatrics.com/upcoming/CEJP\\_2-2020-Zvizdic2.pdf](https://cejpaediatrics.com/upcoming/CEJP_2-2020-Zvizdic2.pdf).
22. Zvizdic Z, Anic D, Popovic N, **Vranic S**. Acute glans ischemia after circumcision successfully treated with low-molecular-weight heparin and topical dihydrotestosterone. **Medicine (Baltimore)** 2020;99(29):p e21340; doi: 10.1097/MD.00000000000021340
23. Zvizdic Z, **Vranic S**. Decreased number of acute appendicitis cases in pediatric population during the COVID-19 pandemic: Any link? **J Pediatr Surg** 2021;56:199-200. doi: <https://10.1016/j.jpedsurg.2020.08.016>.
24. Zvizdic Z, Moinuddin Z, Summers A, Pasic-Sefic I, Skenderi F, Van Dellen D, **Vranic S**, Augustine T. Successful treatment of encapsulating peritoneal sclerosis in an adolescent boy on long-term peritoneal dialysis: A case report. **Prague Med Rep** 2020;121(4):254-61.
25. Zvizdic Z, Rustempasic N, Sefic Pasic I, Bilalovic N, Chikha A, Mesic A, **Vranic S**. A large, highly vascularized sacrococcygeal teratoma in a preterm male infant: A case report. **Asian J Surg** 2021;44:607-8, doi: 10.1016/j.asjsur.2020.12.027.
26. Zvizdic Z, Selimovic M, Mesic A, Anic D, Misanovic V, Skenderi F, **Vranic S**. Unexpected adrenal pheochromocytoma associated with a generalized tonic-clonic seizure in a prepubertal boy: A case report and literature review. **Medicine (Baltimore)** 2021;100(4):e24303, doi: 10.1097/MD.00000000000024303
27. Ibisevic N, Bajrovic J, Spiritovic D, Saranovic E, Skenderi F, **Vranic S**. A giant, complex fibroepithelial tumor of the breast: Borderline phyllodes combined with tubular adenoma. A rare clinical presentation of a fibroepithelial tumor of the breast. **Acta medica Academica** 2021;50(1):218-20.
28. Zvizdic Z, Milisic E, **Vranic S**. Clamping of a persistent omphalomesenteric duct in the herniated umbilical cord in a 2-day-old infant: A case report. **Pediatrics Int** 2021;63(5):608-9, <https://doi.org/10.1111/ped.14598>

29. Zvizdic Z, Chikha A, **Vranic S**. Balanitis xerotica obliterans shortly after hand, foot, and mouth disease in a 5-year-old boy: Coincidence or consequence? **Asian J Surg**. 2021;44(5):773-4, doi: 10.1016/j.asjsur.2021.02.014.
30. Zvizdic Z, Sefic-Pasic I, Mesic A, Terzic S, **Vranic S**. The complete spectrum of pentalogy of Cantrell in one of a set of dizygotic twins: A rare congenital anomaly. **Medicine (Baltimore)** 2021; 100(14):e25470. doi: 10.1097/MD.00000000000025470.
31. Zvizdic D, Bulja D, Sidran A, Skenderi F, Zvizdic Z, **Vranic S**. Isolated orbital hemangioma treated successfully with oral propranolol in a 2-month-old infant: Case report and literature review. **Am J Ophthalmol Case Reports** 2021;22:101095, <https://doi.org/10.1016/j.ajoc.2021.101095>.
32. Zvizdic Z, Pasic Sefic I, Milisic E, Jonuzi A, **Vranic S**. Soccer-related severe blunt splenic injury in a young goalkeeper. **J Pediatric Surg Case Reports** 2021;69:101879, <https://doi.org/10.1016/j.epsc.2021.101879>.
33. **Vranic S**, Damjanov I. Advances in Diagnostic and Molecular Pathology (Editorial). **Acta Med Academica** 2021;50(1):1-3.
34. Zvizdic Z, Milisic E, Jonuzi A, **Vranic S**. Umbilical cord hernia associated with complete evagination of the patent omphalomesenteric duct and prolapse of adjacent ileal limbs. **Asian J Surg** 2021;44(8):1087-8, <https://doi.org/10.1016/j.asjsur.2021.05.022>
35. Zvizdic Z, Jonuzi A, Sefic Pasic I, **Vranic S**. Twisting of a giant cystic Meckel's diverticulum in a toddler: A case report and brief literature review. **Central Eur J Paediatrics** 2022;18(1):27-30, DOI 10.5457/p2005-114.312
36. Zvizdic Z, Milisic E, Ibisevic N, Sefic Pasic I, **Vranic S**. Appendiceal carcinoid in a pediatric patient with Peutz-Jeghers syndrome: A case report and comprehensive literature review. **Medicine (Baltimore)** 2021 Oct 1;100(39):e27389. doi: 10.1097/MD.00000000000027389.
37. Jonuzi A, Zvizdic Z, Karavdić K, Milisic E, Sefic Pasic I, Mesic A, Kulovac B, **Vranic S**. Adrenal abscess in a preterm neonate with sepsis. **J Pediatric Surg Case Reports** 2021;75:102094, <https://doi.org/10.1016/j.epsc.2021.102094>
38. Zvizdic Z, Jonuzi A, Sefic Pasic I, **Vranic S**. Bilateral Morgagni hernia in a two-month-old infant with a history of umbilical cord hernia status repair as a neonate. **Asian J Surg** 2022 March 22, Epub Ahead of Print, <https://doi.org/10.1016/j.asjsur.2022.03.040>
39. **Vranic S**. Comment on the manuscript "Histological subtype is associated with PD-L1 expression and CD8+ T-cell infiltrates in triple-negative breast carcinoma" by Salisbury et al. (Ann Diagn Pathol 2022; 57: 151901, <https://doi.org/10.1016/j.anndiagpath.2022.151901>) **Ann Diagn Pathol** 2022;58:151938, <https://doi.org/10.1016/j.anndiagpath.2022.151938>.
40. Zvizdic Z, Sefic-Pasic I, Ibisevic N, Murtezic S, **Vranic S**. Large juvenile cystic adenomyoma in an adolescent girl: A case report and literature review. **J Pediatric Surg Case Reports** 2022;81:102258, <https://doi.org/10.1016/j.epsc.2022.102258>
41. Zvizdic D, Zvizdic Z, **Vranic S**. An infant with ankyloblepharon filiforme adnatum associated with a cleft lip and palate: A case report. **Asian J Surg** 2022 June 10 Epub Ahead Print, <https://doi.org/10.1016/j.asjsur.2022.05.116>.
42. Redzepagic J, Karavdic K, Firdus A, Kuric H, Bulja D, Ibisevic N, Zvizdic Z, **Vranic S**. A giant polypoid gastric heterotopia of the ileum as a cause of intussusception in an adolescent. **Acta Medica Academica** 2022;51(2), <http://www.ama.ba/upcoming/Acta%20Medica%20Academica%202022%20Redzepagic.pdf>.
43. Zvizdic Z, **Vranic S**. How to deal with rare pediatric surgical diseases in the small developing country with limited resources: Insights from Bosnia and Herzegovina. **J Pediatr Surg** 2022;57:1033, <https://doi.org/10.1016/j.jpedsurg.2022.06.009>
44. Zvizdic Z, Milisic E, Jonuzi A, Vesnic S, Milisic L, Sefic I, **Vranic S**. Successful minimally invasive management of nonvascular grade IV blunt renal trauma with complete transection in a 7-year-

- old girl: A case report. **J Pediatric Surg Case Reports** 2022;86:102455, <https://doi.org/10.1016/j.epsc.2022.102455>
45. Alaghehbandan, R., Agaimy, A., Ali, L. *et al.* A tribute to Prof. Ondrej Hes, MD, PhD (1968–2022). **Mod Pathol** 2022;35(12):2023-4, <https://doi.org/10.1038/s41379-022-01159-8>
  46. Mujić M, **Vranić S**, Skenderi F. Bosnian Journal of Basic Medical Sciences becomes Biomolecules and Biomedicine. **Biomol Biomed** 2023;23(1):1. <https://doi.org/10.17305/bjbms.2022.8686>
  47. Zvizdic Z, Bukvic M, **Vranic S**. A late-diagnosed complete intravaginal testicular torsion with preserved blood flow and viable testis in an adolescent: A case report. **Asian J Surg** 2023 Feb 1 Epub Ahead of Print, <https://doi.org/10.1016/j.asjsur.2023.01.060>.

#### **Publications under review:**

1. Kheraldine H, Gupta I, Al Farsi H, Cyprian FS, **Vranić S**, Al Moustafa AE. Combination of Dasatinib and PD-L1 inhibitors prevents the progression of epithelial-mesenchymal transition and dramatically blocks cell invasion of HER2-positive breast cancer cells *via* PI3K/AKT and  $\beta$ -catenin pathways. Resubmitted, October 2022.
2. Ahmed MB, Al Lahham S, Aljasseem G, Asnaf AAH, Alyazji ZTN, Omari RY, Al-Mohannadi FS, Alsherawi A, **Vranic S**. Surgical management and outcomes of traumatic global brachial plexus injury: A concise review. Submitted, August 2022.
3. Markota Cagal, A, Glibo M, Karin-Kujundzic V, Serman A, **Vranic S**, Serman L, Bukvic Mokos Z. Hedgehog signaling pathway inhibitors in the treatment of basal cell carcinoma. To be submitted, December 2022.
4. Zvizdic Z, Hukic L, Dedeic Ljubovic A, Milisic E, Jonuzi A, **Vranic S**. Epidemiology and early bacterial colonization of minor and moderate pediatric burns: A retrospective study from a developing country. Submitted, November 2022.
5. Shaker N, **Vranic S**, Ajkunic A, Asgari M, Phelps R, Niedt G. Hyperpigmented mycosis fungoides masquerading as longstanding lichen planus pigmentosus: a diagnostic pitfall. Submitted, November 2022.
6. Tomic K, Karan Krizanac D, Skenderi F, Krpina K, Carapina Bilic A, Galic K, Gatalica Z, **Vranic S**. Comprehensive genomic profiling of a metastatic small cell lung carcinoma with a complete and long-term response to atezolizumab: A case report. Submitted, January 2023.
7. Fernandes Q, Gupta I, Murshed K, Abo Samra H, Al-Thawadi H, **Vranic S**, Petkar M, Rathnaiah GB, Al Moustafa AE. Coinfection of HPVs is Associated with Advanced Stage in Colorectal Cancer Patients from Qatar. Submitted, January 2023.
8. Fernandes Q, Gupta I, Murshed K, Samra KA, Al-Thawadi H, **Vranic S**, Petkar M, Rathnaiah GB, Al Moustafa AE. Co-Presence of High-Risk HPVs and EBV and their association with clinicopathological features of colorectal cancer in the State of Qatar. To be submitted, February 2023.

#### **Other peer-reviewed papers (non-indexed journals)**

1. Selak I, Bilalović N, **Vranić S**, Šabanović E. Malignant Lymphoma in Sarajevo Region according to WHO Classification in periods 1989-1991 (before the war) and 1997-1999 (after the war). *Radovi Akademije nauka i umjetnosti Bosne i Hercegovine* 2003;31:131-50.
2. Serdarevic F, **Vranic S**, Dizdarevic J, Masic I, Ridjanovic Z. Towards evidence based clinical practice guidelines: the case of Bosnia and Herzegovina. *AIM* 2008;16:88-93.

3. Resić H, Kukavica N, **Vranić S**, Šahović V, Ćorić A, Avdagić M, Helać-Cvijetić Dž. Malignancies in patients on dialysis in Center for Dialysis Clinical Center University of Sarajevo. Med Zurnal 2008;14:86-88.
4. **Vranić S**, Gatalica Z. Pathology of Hereditary Breast Carcinoma. Med Zurnal 2010;16(4, suppl.1):27-30.
5. Udovicic-Gagula D, Skenderi F, Gornjakovic S, Ibisevic N, Chikha A, **Vranić S**, Djuran A. Uterine cervix metastatic squamous cell carcinoma to the Ampulla of Vater: A case report with review of the literature. J Health Sci 2013;3(2):1-4.
6. Jurcic P, Kruslin B, Gatalica Z, Sanati S, **Vranić S**. Breast carcinoma with neuroendocrine features: a brief review. Endocr oncol metab 2016;2(2):138-45.

### **Reviews and professional articles (on-line only)**

1. **Vranić S**. Review of Diagnostic, Prognostic, and Therapeutic Value of Gene Signatures. Doody's Online Review-Service (on-line). Available at: <http://www.doody.com> (Accessed July, 2012).
2. **Vranić S**. Review of The Washington Manual of Surgical Pathology. Doody's Review Service (on-line). Available at: <http://www.doody.com> (Accessed Jan. 2009).
3. Kapetanović A, **Vranić S**. Two for one! Melanoma and fibrocystic breast disease. Dermatopathol: Pract & Conc 2010;16(3):15 Available at: <http://www.derm101.com>
4. **Vranić S**. Topoisomerase II alpha (TOP2A) (review). Available at: [www.pathologyoutlines.com](http://www.pathologyoutlines.com)
5. Vranic S. The School of Life: A collaboration between Britain and Bosnia – the Bryan Warren School of Pathology – is bringing education to trainees with limited access (2017), <https://thepathologist.com/outside-the-lab/the-school-of-life>
6. AlAhmad YFM, Abdelhafez IHE, Skenderi F, **Vranić S**. When Progress Becomes Predation. The Pathologist (2019), <https://thepathologist.com/outside-the-lab/when-progress-becomes-predation>
7. Terlević R, **Vranić S**. **SSTR2A**. PathologyOutlines.com website (2019). <https://www.pathologyoutlines.com/topic/stainsSSTR2A.html>
8. Terlević R, **Vranić S**. Cytokeratin 5/6 and CK5. PathologyOutlines website (2019). <https://www.pathologyoutlines.com/topic/stainsck5and6.html>
9. Terlević R, Vranić S. **OCT 3/4**. PathologyOutlines.com website (2020). <http://www.pathologyoutlines.com/topic/stainsoct340.html>

### **Translations**

1. Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell 2000; 100:57-70; Translation into Bosnian. Sarajevo: Glas medicinara, 2005, pp 38.

### **Books/chapters**

1. Damjanov I, **Vranić S**, Skenderi F. Review of Gynecologic and Breast Pathology. Jaypee Brother Medical Publishers (P) Ltd. 2017 ([https://www.amazon.com/Review-Gynecologic-Breast-Pathology-Damjanov/dp/9352700473/ref=sr\\_1\\_1?ie=UTF8&qid=1506668227&sr=8-1&keywords=review+of+gynecologic+and+breast+pathology](https://www.amazon.com/Review-Gynecologic-Breast-Pathology-Damjanov/dp/9352700473/ref=sr_1_1?ie=UTF8&qid=1506668227&sr=8-1&keywords=review+of+gynecologic+and+breast+pathology))



2. **Vranic S.**, Gatalica Z. (2018) Apocrine Carcinoma. In: van Krieken J. (eds) Encyclopedia of Pathology. Breast Pathology. Springer, Cham.  
([https://link.springer.com/referenceworkentry/10.1007/978-3-319-28845-1\\_4693-1](https://link.springer.com/referenceworkentry/10.1007/978-3-319-28845-1_4693-1))
3. Gatalica Z, Feldman R, Vranic S, Spetzler D. Immunohistochemistry-enabled Precision Medicine. In: D. Von Hoff and H. Han (eds.), Precision Medicine in Cancer Therapy, Cancer Treatment and Research 178, 2019. [https://doi.org/10.1007/978-3-030-16391-4\\_44](https://doi.org/10.1007/978-3-030-16391-4_44).
4. Provenzano E, Gatalica Z, **Vranic S.** Carcinoma with apocrine differentiation. In: **WHO Classification of Tumours 5th Edition - Tumours of the Breast. IARC, Lyon 2019.**  
<http://apps.who.int/bookorders/anglais/detart1.jsp?codlan=1&codcol=70&codcch=5002>
5. **Vranic S.**, Gatalica Z. Apocrine Carcinoma. In: Sapino A, Kulka J (eds) Breast Pathology. Encyclopedia of Pathology. Springer, Cham, 2020. <https://doi.org/10.1007/978-3-319-62539-3>
6. Gupta I, Ghabreau L, Al-Thawadi H, Yasmeen A, **Vranic S.**, Al Moustafa AE, Malki MI. Co-Incidence of Human Papillomaviruses and Epstein–Barr Virus is Associated with High to Intermediate Tumor grade in Human Head and Neck Cancer in Syria. **Front Oncol** 2020;10:1016, <https://doi.org/10.3389/fonc.2020.01016> In: Advances in the involvement of Human Papillomavirus in head and neck squamous cell carcinoma. Edited by: Jerome R. Lechien, Stéphane Hans, and Francois Mouawad. Frontiers in Oncology, 2022 (E-book, available: <https://www.frontiersin.org/research-topics/12156/advances-in-the-involvement-of-human-papilloma-virus-in-head-and-neck-squamous-cell-carcinoma#overview>)
7. Allouch S, Gupta I, Malik I, Al Farsi HF, **Vranic S.**, Al Moustafa AE. Breast cancer during pregnancy: A marked propensity to triple-negative phenotype. **Front Oncol** 2020;10:10:580345. Lambertini, M., Poorvu, P., Kim, H. J., eds. (2022). Breast Cancer in Young Women. Lausanne: Frontiers Media SA. doi: 10.3389/978-2-88976-006-0, E-book, available: <https://www.frontiersin.org/research-topics/13438/breast-cancer-in-young-women>

## Abstracts/conference proceedings

1. **Vranić S**, Bilalović N, Selak I. Malignant Lymphoma in Sarajevo Region according to WHO Classification in periods 1989-1991 (before the war) and 1997-1999 (after the war). ISOMS, Groningen, July 9-19, 2002.
2. **Vranić S**. Some prognostic factors in breast cancer. ZIMS, Zagreb, 2003.
3. Bilalović N, Berbić-Fazlagić J, Robović Z, **Vranić S**, Čikić B, Selak I. Immunohistochemical analysis significance in diagnostic assessment of malignant lymphoma. Morphology in Science and Praxis. Sarajevo, September 25-27, 2003.
4. Bilalović N, Hasanagić S, **Vranić S**, Bešlija S, Bašić H, Selak I. Although Bcl-2 expression is associated with better outcome, Bcl-2 is not independent prognosticator of overall survival (OS) and relapse-free survival (RFS) in breast cancer. Eur J Cancer Suppl 2004;3(2):180.
5. Bilalović N, **Vranić S**, Hasanagić S, Bašić H, Tatarević A, Selak I. Cyclin D1 is good prognosticator in breast cancer. Acta Clin Croat 2004;43(2):93.
6. Bilalović N, **Vranić S**, Hasanagić S, Selak I. Epstein-Barr virus expression in breast cancer. Acta Clin Croat 2004;43(2):92.
7. **Vranić S**, Bilalović N. Cyclin D1 expression in breast cancer. Abstractbook of «15th ESC», Berlin, Germany, October 19-23, 2004.
8. Bašić H, Bilalović N, **Vranić S**, Tatarević A. Estrogen and Progesterone receptor expression more precisely determined by monoclonal H-score immunohistochemistry than by polyclonal antibodies, impact on breast cancer outcome. Cancer control in developing countries, Translating Knowledge into Effective Action. INCTR Annual Meeting. Abstracts; Cairo, Egipt. Cairo: s.n.; 2004: No. 42 Abst.
9. Bašić H, Bilalović N, Tatarević A, **Vranić S**. Correlation between the prognostic value of Bcl-2 and standard clinical and histopathological parameters in breast cancer patients. Ann Oncol 2004;15(Suppl.3):iii58 (No. 219P).  
**Notes: 29th ESMO Congress, Vienna, Austria, 29 Oct – 2 Nov 2004.**
10. Bilalović N, **Vranić S**. Expression of CD34 as a vascular marker in invasive breast cancer. Book of Abstracts of 3rd Croatian Congress of Pathology and Forensic Medicine, May 8- 11, 2005, Opatija, Croatia, p. 49.
11. Bilalović N, **Vranić S**. CD10 expression in breast cancer. Virchows Arch 2005;447(2):240.  
**Note: 20th European Congress of Pathology, September 3-8, 2005, Paris, France.**
12. **Vranić S**, Tanović H, Lazović E, Pašanović A, Bilalović N. Abdominal anaplastic large cell lymphoma with spleen and pancreas involvement. Abstractbook of the First Congress of Surgery of Federation of Bosnia and Herzegovina with international participation. April 12-15, 2006, Sarajevo.
13. Bilalović N, Tanović S, Adrović A, Kukavica M, **Vranić S**. Expression of cyclin D1 in human colorectal cancer and its correlation with prognosis. First Congress of Surgery of Federation of Bosnia and Herzegovina with international participation. April 12-15, 2006, Sarajevo.
14. **Vranić S**, Bilalović N, Čerimagić Z, Gatti A, Kayser K. Secondary leiomyomatosis in a Bosnian male: A case report. Acta Clin Croat 2006;45(2):163.  
**Note: 17th Ljudevit Jurak International Symposium on Comparative Pathology, Zagreb, Croatia, June 2-3, 2006.**
15. **Vranić S**, Muftić K, Bešlić Š, Bilalović N. Recurrent malignant granular cell tumor of the breast: A case report. Mod Pathol 2006;19(suppl.3):26.  
**Note: XXVI Congress of the International Academy of Pathology (IAP), Montreal, Canada, September 15-20, 2006.**

16. **Vranić S**, Lazovic E, Obralic N, Gavrankapetanovic F, Bilalovic N. The correlation of morphological features of transitional cell carcinoma of urinary bladder with different biological parameters. *Mod Pathol* 2006;19(suppl.3):88-89.  
**Note: XXVI Congress of the International Academy of Pathology (IAP), Montreal, Canada, September 15-20, 2006.**
17. **Vranić S**, Đuričić S, Suljević I, Bilalović N. Unrecognized epignathus followed by airway obstruction as a cause of neonatal death. *Acta Clin Croat* 2007;46(2):183.  
**Note: 18th Ljudevit Jurak International Symposium on Comparative Pathology, Zagreb, Croatia, June 1-2, 2007.**
18. Fočo F, **Vranić S**, Serdarević F, Čičkušić E, Gurjeva O, Bilalović N. Peritumoral expression of p53 in oral cancer and its correlation with relapse. *Oral Oncology Suppl* 2007;2(1):172-3.  
**Note: 1st World Congress of the International Academy of Oral Oncology. Amsterdam, the Netherlands, P136, May 17-20, 2007.**
19. **Vranic S**, Cimic A, Pasanovic A, Hodzic D, Bilalovic N. Cyclin D1 and Ki-67 expression in columnar cell lesions of the breast. *Virchows Arch* 2007;451(2):296.  
**Note: 21st European Congress of Pathology, Istanbul, September 8-13, 2007.**
20. Bilalovic N, Cimic A, **Vranic S**, Bejtovic I, Chikha A, Gavrankapetanovic F. Endoglin (CD105) expression in non-small cell lung cancer and its correlation with EGFR, CD34 and other histopathological parameters: Pilot study. *Virchows Arch* 2007; 451(2):528.  
**Note: 21st European Congress of Pathology, Istanbul, September 8-13, 2007**
21. Cimic A, **Vranic S**, Bilalovic N. Intraabdominal localization of extraskeletal myxoid chondrosarcoma: Case report. *Virchows Arch* 2007;451(2):573.  
**Note: 21st European Congress of Pathology, Istanbul, September 8-13, 2007.**
22. Bilalovic N, Cimic A, **Vranic S**, Vidovic Z, Kayser K. Diagnostic challenge on frozen section: Pulmonary papillary pneumocytoma (sclerosing hemangioma) and importance of clinical data. *Virchows Arch* 2007;451(2):529  
**Note: 21st European Congress of Pathology, Istanbul, September 8-13, 2007.**
23. Bilalovic N, Chikha A, **Vranic S**. Calcifying Epithelial Odontogenic Tumor with the Amyloid deposits (Pindborg tumor): Report of a Case. *Acta Med Sal* 2007;36(Suppl.1):49  
**Note: 2nd Congress of the Otolaryngology and Cervicofacial Surgery of Bosnia and Herzegovina, Sarajevo, October 27-30, 2007.**
24. Lojo-Kadrić N, Kapur L, Ramić J, Bešlija S, Obralić N, Bilalović N, **Vranić S**, Bajrović K. Identification of BRCA 1 mutation in breast and ovarian cancer patients diagnosed at age under 40. *Eur J Hum Genet* 2007;15(Suppl.1):149.
25. Lojo-Kadrić N, Kapur L, Ramić J, Bešlija S, Obralić N, Bilalović N, **Vranić S**, Bajrović K. Identifikacija mutacija na BRCA1 genu u skupini pacijenata sa dijagnozom karcinoma dojke i ovarija prije 40 – te godine života.  
**Note: International Scientific Symposium „Molecular genetic research today and it's application possibilities“. Tuzla, October 11, 2008.**
26. Gatalica Z, Deng H, Lee LMJ, **Vranic S**, Wang ZY. Pure Apocrine Carcinomas of the Breast Express ER-alpha 36, A Novel Alternatively Spliced Variant of Human Estrogen Receptor-alpha (ER-alpha 66).  
**Note: 31st San Antonio Breast Cancer Symposium. December 10-14, 2008.**
27. Gatalica Z, **Vranic S**. Invasive Apocrine Carcinomas Are Molecularly Diverse Group Of Breast Cancers. *Mod Pathol* 2010;23(Suppl.1):46A.  
**Note: United States & Canadian Academy of Pathology Annual Meeting, Washington DC, USA, March 20-26, 2010.**

28. **Vranic S**, Frkovic-Grazio S, Bilalovic N, Palazzo J, Gatalica Z. Epidermal Growth Factor Receptors And Topoisomerase II Alpha In Primary Adenoid Cystic Carcinomas Of The Breast. *Mod Pathol* 2010;23(Suppl.1):76A.  
**Note: United States & Canadian Academy of Pathology Annual Meeting, Washington DC, USA, March 20-26, 2010.**
29. **Vranic S**, Frkovic-Grazio S, Palazzo J, Gatalica Z. IMP3, a novel basal phenotype marker, is commonly overexpressed in triple negative adenoid cystic carcinomas of the breast but not in triple negative apocrine carcinomas. *Histopathology* 2010; 57(Suppl.1):26-7.  
**Note: XXVIII Congress of the International Academy of Pathology, São Paulo, Brazil, October 10-15, 2010.**
30. **Vranic S**, Frkovic-Grazio S, Bilalovic N, Gatalica Z. Evaluation of angiogenesis in adenoid cystic carcinoma of the breast. *Virchows Arch* 2011;459(suppl.1):S84.  
**Note: 23rd European Congress of Pathology, Helsinki, Finland, August 27 – September 1, 2011**
31. Krakonja F, Karović J, Muftić K, Silajdžić S, **Vranić S**. Infarkcija fibroadenoma kod trinaestogodišnje djevojčice: Prikaz slučaja (Infarcted fibroadenoma of the breast in a 13 year-old girl: Case report).  
**Note: 4th Congress of Radiology of Bosnia and Herzegovina with international participation. Sarajevo, September 30 – October 2, 2011.**
32. **Vranic S**. Predictive markers in ER/PR negative breast carcinomas. Symposium „Savremeni pristup u tretmanu karcinoma dojke“, Akademija nauka i umjetnosti Bosne i Hercegovine , November 23, 2011.
33. Bilalovic N, Hodzic D, Omanovic A, **Vranic S**. Granulocytic Sarcoma of the Breast. Abstract Book, 2nd Congress of Pathologists in Bosnia and Herzegovina with international participation; pp 67-68.  
**Note: 2nd Congress of Pathologists in Bosnia and Herzegovina with international participation, Banja Luka, May 10-12, 2012.**
34. **Vranic S**. Human Epidermal Growth Factor Receptors 1 and 2 (HER1 and HER-2/neu) Status in Invasive Apocrine Carcinoma of the Breast. In: Research Abstracts and Research Proposals of the PhD Program Biomedicine and Health Sciences, Zagreb University School of Medicine. Zagreb: Medicinska naklada, 2012, p. 21.  
**Note: PhD Day, Zagreb University School of Medicine, Zagreb, Croatia, May 25, 2012.**
35. **Vranic S**, Hes O, Gatalica Z. Low frequency of HIF-alpha over-expression in germ cell tumors of the testis. *Histopathology* 2012;61(suppl.1):225.  
**Note: XXIX Congress of the International Academy of Pathology. Cape Town, South Africa, September 30 – October 5, 2012.**
36. Chikha A, Jukovic-Bihorac F, Skenderi F, Krakonja F, Bilalovic N, **Vranic S**. Infarcted fibroadenoma of the breast: Report of two cases. *Histopathology* 2012;61(suppl.1):15.  
**Note: XXIX Congress of the International Academy of Pathology. Cape Town, South Africa, September 30 – October 5, 2012.**
37. Costa LJ, Justino A, Gomes M, Alvarenga CA, Gerhard R, **Vranic S**, Gatalica Z, Machado JC, Schmitt F. Comprehensive genetic characterization of apocrine lesions of the breast. *Cancer Res* 2013;73(8):2013.  
**Note: American Association for Cancer Research Annual Meeting 2013, April 6-10, 2013, Washington, DC.**
38. **Vranic S**, Castellano I, Marchiò C, Botta C, Tondat F, di Celle PF, Scalzo MS, Sapino A. Immunohistochemical and molecular profiling of invasive apocrine carcinoma of the breast. *Virchows Arch* 2013;463(2):250-1.  
**Note: 25th European Congress of Pathology, Lisbon, August 31 – September 4, 2013.**

39. Millis S, Bryant D, Basu G, Bender R, **Vranic S**, Gatalica Z, Vogelzang N. Molecular profiling of infiltrating urothelial carcinoma of the bladder. *J Clin Oncol* 2014;32 (suppl.4):Abstr. 311.  
**Note: 2014 ASCO Genitourinary Cancers Symposium, January 30 – February 1, 2014, San Francisco, USA.**
40. Kos M, **Vranic S**, Djuricic S, Hes O, Basu G, Gatalica Z. Renal cell carcinomas in pediatric population: A comprehensive molecular profiling of 7 cases. *Virchows Arch* 2014;465(suppl.1):S195.  
**Note: 26th European Congress of Pathology, London 2014.**
41. Kovari B, Vranić S, Kocsis L, Sapino A, Cserni G. Growth hormone releasing hormone receptor (GHRH-R) expression in various types of apocrine epithelial lesions - Apocrine breast carcinomas and cutaneous tumors with apocrine features. *Virchows Arch* 2014; 465(suppl.1):S102.  
**Note: 26th European Congress of Pathology, London 2014.**
42. Ghazalpour A, Kiss O, **Vranic S**, Kulka J, Gatalica Z. Identification of differentially expressed miRNAs and their targets in adenoid cystic carcinoma of the breast. *Virchows Arch* 2014;465(suppl.1):S322.  
**Note: 26th European Congress of Pathology, London 2014.**
43. Kiss O, Ghazalpour A, **Vranic S**, Kulka J, Gatalica Z. Cyclin D1 and Bcl-2 expression of breast- and salivary gland-derived adenoid cystic carcinoma: an immunohistochemical study. *Virchows Arch* 2014;465(suppl.1):S118.  
**Note: 26th European Congress of Pathology, London 2014.**
44. Peckova K, Martinek P, **Vranic S**, Kokoskova B, Hora M, Michal M, Hes O. Aggressive and non-aggressive translocation t(6;11) renal cell carcinoma: Comparative study of 6 cases. *Virchows Arch* 2014;465(suppl.1):S160.  
**Note: 26th European Congress of Pathology, London 2014.**
45. Skenderi F, Ulamec M, **Vranic S**, Bilalovic N, Peckova K, Rotterova P, Kokoskova B, Branzovsky J, Michal M, Hes O. Cystic renal oncocytoma and tubulocystic renal cell carcinoma: Morphologic and immunohistochemical study. *Pathology* 2014;46(S2):135-6.  
**Note: 30th IAP Congress, Bangkok 2014.**
46. Gatalica Z, **Vranic S**, Basu G, Millis S, Voss A. Biomarkers of targeted therapies in phyllodes sarcomas of the breast. *Ann Oncol* 2014; 25(suppl.4):iv110-iv115.  
**Note: ESMO Madrid 26-30 September, 2014.**
47. Gatalica Z, **Vranic S**, Basu G, Lynch HT. Thymidylate Synthase over-expression underlies the observed lack of 5-FU therapy benefit for MSI-H colorectal cancers. *Ann Oncol* 2014; 25(suppl.4):iv167-iv209.  
**Note: ESMO Madrid 26-30 September 2014.**
48. Silva E, Gatalica Z, **Vranic S**, Basu G, Sandeep R, Voss A. Molecular profiling of angiosarcomas of the breast. *Ann Oncol* 2014;25(suppl.4):iv494-iv510.  
**Note: ESMO Madrid, 26-30 September 2014.**
49. Skenderi F, Hes O, **Vranic S**, Kruslin B. Molecular profiling of tubulocystic renal cell carcinoma. Dan doktorata (PhD Day) 2014, University of Zagreb School of Medicine, 2014, p. 178. (poster code: B-23-153)

50. Gatalica Z, Bilalovic N, Palazzo J, Bender RP, Swensen J, Millis SZ, **Vranic S**, Von Hoff DD, Arceci RJ. Disseminated histiocytoses: Biomarkers beyond BRAFV600E. *J Clin Oncol* 2015;33(suppl. abstr. e22207).  
**Note: ASCO 2015, Chicago, 27 May -1 June 2015.**
51. Gatalica Z, Vijayvergia N, **Vranic S**, Xiu J, Reddy S, Lynch HT, El-Deiry WS. Therapeutic biomarker differences between MSI-H and MSS colorectal cancers. *J Clin Oncol* 2015;33(suppl. abstr. 3597).  
**Note: ASCO 2015, Chicago, 27 May – 1 June 2015.**
52. Cesarec S, Kirgin MS, Skenderi F, Ulamec M, Stimac G, Chikha A, **Vranic S**, Kruslin B. Sarcomatoid variant of urothelial carcinoma of the urinary bladder. A study of 27 cases. *Virchows Arch* 2015;467(suppl.1):S263.  
**Note: 27th European Congress of Pathology, Belgrade 2015.**
53. Gatalica Z, Burnett K, Bender R, Feldman R, Vranic S, Reddy S. BRAF mutations are potentially targetable alterations in a wide variety of solid cancers. *Eur J Cancer* 2015; 50(suppl.3):S31.  
**Note: 40th ESMO/18th ECCO Vienna 2015.**
54. Gatalica Z, Bilalovic N, **Vranic S**, Arguello D, Reddy S, Ghosh N. PD-1 and PD-L1 expression in lymphomas. *Blood* 2015;126(23):3899.  
**Note: Annual meeting, American Society of Hematology, December 2015**
55. Gatalica Z, **Vranic S**, Ghazalpour A, Xiu J, Ocal IT, McGill J, Bender R, Disciano E, Sanati S, Reddy S, Pockaj B. Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast. *Cancer Res* 2016;76(4 Suppl): Abstract nr P4-09-19.  
**Note: San Antonio Breast Cancer Conference, December 2015.**
56. Gatalica Z, **Vranic S**, Rose I, Teresi P, Feldman R, Bender R. Concordance of anti-BRAF p.V600E immunohistochemistry with BRAF gene sequence in solid tumors carrying diverse BRAF mutations. *Mod Pathol* 2016;29(suppl.2):454A (Abstract#1797).  
**Note: USCAP Meeting, Seattle 12-18 March 2016.**
57. Feldman R, Gatalica Z, **Vranic S**, Bender R, Reddy S, Ghazalpour A. Caveolin-1: Beyond a marker for basal-like breast cancers. *Cancer Res* 2016;76(14 Supplement):3928.  
**Note: American Association for Cancer Research Annual Meeting 2016.**
58. Arguello D, Gatalica Z, **Vranic S**, Reddy S, Vander Walde A. Analysis of MET-amplified solid tumors using chromogenic in situ hybridization (CISH). *Cancer Res* 2016;76(14 Supplement):396.  
**Note: American Association for Cancer Research Annual Meeting 2016.**
59. Kurtovic-Kozaric A, Kugic A, Hasic A, Beslija S, Ceric T, Pasic A, **Vranic S**, Kopic D, Iljazovic E, Todorovic Barbuscia J, Ibisevic N, Kurtovic S. The effects of delayed imatinib mesylate treatment on outcome in patients with GIST. *J Clin Oncol* 2016;34(suppl; abstr e22518).  
**Note: ASCO annual meeting, Chicago 2016.**
60. Skenderi F, Ulamec M, **Vranic S**. Clinico-pathological and molecular characterization of tubulocystic subtypes of renal tumors. *Dan doktorata (PhD Day) 2016, University of Zagreb School of Medicine, 2016, p. 75. (poster code: R-B-23-31)*
61. Fabijanovic D, Zunic I, Nikuseva Martic T, Skenderi F, Serman L, **Vranic S**. The members of Wnt pathway SFRP1, SFRP3 and DVL1 are downregulated in testicular germ cell tumors. *Virchows Arch* 2016;469(suppl.1):S218-9.  
**Note: ECP/IAP 2016, Cologne.**

62. Skenderi F, Ulamec M, **Vranic S**, Michal M, Hes O. Warthin-like papillary renal cell carcinoma with prominent lymphocytic infiltrate: morphologic and immunohistochemical study. *Virchows Arch* 2016;469(suppl.1):S14.  
**Note: ECP/IAP 2016, Cologne.**
63. Skenderi F, Ibisevic N, Topcagic J, Bilalovic N, **Vranic S**. Breast cancer incidence, demographic and pathological characteristics in Bosnia and Herzegovina. *Virchows Arch* 2016;469(suppl.1):S58.  
**Note: ECP/IAP 2016, Cologne.**
64. Ibisevic N, Skenderi F, Chikha A, Bilalovic N, **Vranic S**. Cervical cancer incidence, demographic and pathological characteristics in Bosnia and Herzegovina. *Virchows Arch* 2016;469(suppl.1):S289.  
**Note: ECP/IAP 2016, Cologne.**
65. Chikha A, Ibisevic N, Skenderi F, Bilalovic N, Kulovac B, Selimović M, **Vranic S**. Spermatocytic seminoma: Report of three cases. *Virchows Arch* 2016; 469(suppl.1):S236.  
**Note: ECP/IAP 2016, Cologne.**
66. **Vranic S**, Jin J, Kimbrough J, Ghosh N, Bilalovic N, Arguello D, Veloso Y, Hendershot T, Dizdarevic A, Reddy S, Gatalica Z. PD-L1 status in refractory lymphomas. *Ann Oncol* 2016;27(suppl.6):vi317-8.  
**Note: ESMO, Copenhagen, 7-10 October 2016.**
67. Gatalica Z, **Vranic S**, Feldman R. Apocrine carcinoma of the breast. *Virchows Arch* 2016, suppl., in press (ECP/IAP 2016, Cologne).
68. Gatalica Z, Ghazalpour A, Swensen J, Bender R, **Vranic S**, Feldman R, Reddy S. Molecular profiling of locally advanced/metastatic olfactory neuroblastomas (Esthesioneuroblastomas). *Ann Oncol* 2016;27(suppl.6):vi334.  
**Note: ESMO, Copenhagen, 7-10 October 2016.**
69. Gatalica Z, Feldman R, Ghazalpour A, **Vranic S**. Characterization of neuroendocrine breast carcinomas for biomarkers of therapeutic options. *Cancer Res* 77(4 Suppl):Abstract nr P6-07-27.  
**Note: San Antonio Breast Cancer Symposium December 2016.**
70. Skenderi F, Bilalovic N, Beslagic V, Balta E, Hasanbegovic B, Beslija S, **Vranic S**. Neuroendocrine carcinoma of the breast: A retrospective review 2005-2016. *Folia Medica* 2016;51(suppl.1):33.
71. Ibisevic N, Chikha A, Skenderi F, Bilalovic N, Humačkić Vila A, **Vranic S**. Malignant endometrial PEComa: a case report. *Folia Medica* 2016;51(suppl.1):68.
72. Karin V, Kakarigi L, Skrtic A, Nikuseva Martić T, Ibisevic N, Skenderi F, **Vranic S**, Serman L. Sonic Hedgehog proteins are overexpressed in high-grade serous ovarian carcinomas. *Libri Oncologici* 2016;44(1):38. (Fourth Meeting of the Croatian Association for Cancer Research (Hrvatsko društvo za istraživanje raka, HDIR), November 3-4, 2016.
73. Senarathne J, Gates P, **Vranic S**, Gatalica Z. A comparative analysis of PD-L1 distribution in primary NSCLC and metastatic tumors to the lung. *Mod Pathol* 2017;30(supplement 2s):494A.  
**Note: USCAP Meeting, San Antonio, March 4-10, 2017.**
74. Mahdi Z, Dzinic SH, **Vranic S**, Skenderi F, Sheng S, Beydoun R. Differential Expression and Subcellular Localization of Tumor Suppressor Maspin as a Diagnostic Marker in Gastroesophageal Junction Carcinoma and Its Precursors. *Mod Pathol* 2017;30(supplement 2s):185A.  
**Note: USCAP Meeting, San Antonio, March 4-10, 2017.**
75. Michal M, Kazakov DV, Agaimy A, Michalova K, Grossmann P, Skenderi F, **Vranic S**, Michal M. Whorling Cellular Perineurioma: An undescribed benign tumor mimicking monophasic fibrous synovial sarcoma. *Mod Pathol* 2017;30(supplement 2s):20A.

- Note: USCAP Meeting, San Antonio, March 4-10, 2017.**
76. Demirović A, **Vranic S**, Skenderi F, Perić Balja M, Ulamec M, Vučić M, Krušlin B. Primary neuroendocrine carcinoma of the breast: a diagnostic approach to the rare primary breast malignancy. *Neuroendocrinology* 2017;105(suppl.1):1-338.
- Note: 14th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. Barcelona March 2017.**
77. Gatalica Z, Senarathne J, **Vranic S**. PD-L1 expression patterns in the metastatic tumors to the lung: a comparative study with the primary non-small cell lung cancer. *Ann Oncol* 2017; 28 (suppl\_2): mdx094.003.
- Note: European Lung Cancer Conference 2017.**
78. Karin V, Kardum V, Glibo M, Skrtic A, Nikuseva Martic T, Ibisevic N, Skenderi F, **Vranic S**, Serman L. Methylation-associated silencing of SFRP1 gene in high-grade serous ovarian carcinomas. Proceedings, 10th ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine. Dubrovnik, June 19-24, 2017.
79. Kurtovic-Kozaric A, Kugic A, Hasica A, Ceric T, **Vranic S**, Djuran A, et al. Impact of CD117 Expression on the Survival of GIST Patients. 10th ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine. Dubrovnik, June 19-24, 2017.
80. **Vranic S**. Recent advances in molecular pathology of breast cancer. 26<sup>th</sup> Ljudevit Jurak International Symposium on Comparative Pathology. Book of Abstracts, Zagreb, 2017, p.20.
81. Gatalica Z, Palazzo J, Sanati S, Florento E, Xiu J, Swensen J, Vranic S. Comprehensive molecular profiling of neuroendocrine breast carcinoma reveals biomarkers of targeted treatment. *Mod Pathol* 2018;31(suppl.2):61.
- Note: USCAP Annual Meeting, Vancouver, March 2018.**
82. **Vranic S**, Palazzo J, Swensen J, Xiu J, Florento E, Gatalica Z. Comprehensive molecular profiling of pleomorphic ductal carcinoma of the breast with theranostic implications. *Mod Pathol* 2018;31(suppl.2):112.
- Note: USCAP Annual Meeting, Vancouver, March 2018.**
83. Karin V, Slavica M, Skrtic A, **Vranic S**, Serman L. Hedgehog signaling pathway status in serous ovarian carcinomas. *Mod Pathol* 2018;31(suppl.2):428-9.
- Note: USCAP Annual Meeting, Vancouver, March 2018.**
84. Imamovic D, Bilalovic N, Skenderi F, Beslagic V, Ceric T, Hasanbegovic B, Beslija S, **Vranic S**. Clinicopathologic characteristics of invasive apocrine carcinoma of the breast: A single center experience from a country with limited resources. *Eur J Cancer* 2018;92(suppl.3):S24.
- Note: 11<sup>th</sup> European Breast Cancer Conference 2018, Barcelona, March 2018.**
85. Bonfil DR, Friedman R, **Vranic S**, et al. Discoidin domain receptor 1 (DDR1): A potential suppressor of prostate cancer progression. *Cancer Res* 2018;78(13)(suppl.):1070. (<https://doi.org/10.1158/1538-7445.AM2018-1070>)
- Note: Annual AACR Meeting, Chicago, April 2018.**
86. Karin V, Skrtic A, Skenderi F, Ibisevic N, **Vranic S**, Serman L. The status of SHH and IHH in serous ovarian carcinomas. *Ann Oncol* 2018;29(suppl.3):mdy047.016
- Note: ESMO Targeted Anticancer Therapies, Paris, 5-7 March 2018.**



87. **Vranic S**, Ghabreau L, Al-Thawadi H, Alkhalaf M, Al Moustafa AE. The frequency of Epstein-Barr virus and high-risk human papillomaviruses co-infection in cervical carcinoma samples of Syrian women. Abstract book of Posters and Oral Presentations, XXXII Congress of the International Academy of Pathology, P-06, Abstract No. 053, Amman 2018.
88. AlAhmad YFM, Abdelhafez IHE, Cyprian FS, Skenderi F, Akhtar S, **Vranic S**. Predatory journals in pathology: A comprehensive assessment. Abstract book of Posters and Oral Presentations, XXXII Congress of the International Academy of Pathology, FOP-08-1, Abstract No. 003, Amman, 2018.
89. Chikha A, Ibisevic N, Skenderi F, Junuzovic D, **Vranic S**. A bilateral sex-cord stromal tumor of the testis. Report of the case. Abstract book of Posters and Oral Presentations, XXXII Congress of the International Academy of Pathology, P-18, Abstract No. 10, Amman 2018.
90. Gatalica Z, Senarathne W, **Vranic S**, Pockaj BA. Profiling of metastatic carcinomas to the breast for the biomarkers of immuno-oncology therapy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-10-27.
91. Karin-Kujundzic V, Kardum V, Skrtic A, Skenderi F, **Vranic S**, Serman L. Expression of Dishevelled family proteins DVL1, DVL2 and DVL3 in serous ovarian carcinomas. Proceedings of the 2nd Frankfurt Conference on Quality Control in Life Processes & 8th International p63/p73 Workshop, September 2-6, 2018, Proceedings, pp 112-3 (Poster P1-031).
92. Terlevic R, Perić Balja M, Tomas D, Kruslin B, **Vranic S**, Skenderi F, Demirovic A. Somatostatin receptor expression in neuroendocrine breast cancer. Virchows Arch 2018;473(suppl.1):30. (30<sup>th</sup> European Congress of Pathology, Bilbao 2018).
93. Mardekian S, Senarathne W, Feldman F, Florento E, Swensen J, **Vranic S**, Gatalica Z. Comprehensive molecular profiling of salivary duct carcinomas. Mod Pathol 2019;32(suppl.2):15 (USCAP 2019).
94. **Vranic S**, Sadek KW, Haik MY, Ashour AA, Al Moustafa AA. Water-pipe smoking enhances the progression and invasiveness of human breast cancer cells. Cancer Res 2019 suppl., in press. American Association for Cancer Research (AACR) Annual Meeting 2019.
95. Gatalica S, **Vranic S**, Stafford P, Skenderi F, Swensen J, Xiu J, Spetzler D. Spindle cell carcinoma of the breast: rare cancer with potentially targetable biomarkers. Ann Oncol 2019;30(suppl.3):mdz095.057 (ESMO Breast Cancer 2019, Berlin, May 2-4).
96. **Vranic S**, Arguello D, Contreras E, Cimic A, Gatalica Z. Molecular profiling reveals novel targetable biomarkers in neuroendocrine carcinoma of the uterine cervix. Ann Oncol 2019;(30; suppl. 5):mdz250.065 <https://doi.org/10.1093/annonc/mdz250.065>
97. Mioc P, Karin Kujundzic V, Matijevic R, Skrtic A, **Vranic S**, Serman L. Smoothed protein expression and promoter methylation status in serous ovarian carcinomas. Int J Gynecol Cancer 2019 suppl., in press (ESGO, Athens November 2019).
98. Ziegler C, Mir A, Anandakrishnan S, Farmer A, Contreras E, Richardson D, **Vranic S**, Gatalica Z, Derkach DN. Novel Method for Patient Stratification in Breast Carcinoma Based Upon Spatial Analysis of Tumor Microenvironment. Mol Cancer Therapeut 2019;18(12 Suppl):B094 (AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics October 2019) DOI: 10.1158/1535-7163.TARG-19-B094
99. Abbas T, **Vranic S**, Pennisi P. Histological evaluation of the male rabbit urethra: Regional and age-related variations and their relevance in tissue engineering and reconstructive surgery applications. In The 6th World Congress of the World Federation of Associations of Pediatric Surgery” (WOFAPS 2019): Book of Abstracts. 2019. p. 226
100. Gupta I, Jabeen A, Smatti MK, Al-Thawadi HA, Nasrallah GK, Sultan AA, Alkhalaf M, **Vranic S**, Al Moustafa AE. Human Papillomaviruses and Epstein Barr Virus are prevalent among healthy

- blood donors in Qatar. Proceedings of the 9th Annual Meeting of the Middle-Eastern Association for Cancer Research: Cancer Science from Bench to Clinic, Doha, 2019, pp 95-6 (Abstract#49).
101. Skenderi F, Palazzo J, Swensen J, Contreras E, Florento E, Gatalica Z, **Vranic S**. Molecular Profiling of Clear Cell Carcinoma of the Breast Reveals Novel Targetable Biomarkers. *Mod Pathol* 2020;33(suppl.2):263 (poster#267) (USCAP 2020).
  102. Gupta I, Jabeen A, Skenderi F, Malki MI, Al-Thawadi H, Al Moustafa AE, **Vranic S**. High-risk Human Papillomaviruses (HPV) and Epstein - Barr virus (EBV) are Commonly Present in Rectal Cancer. *Mod Pathol* 2020;33(suppl.2):676. (poster#683) (USCAP 2020).
  103. Nagi K, Gupta I, AlThawadi HA, Jabeen A, Malki MI, **Vranic S**, AlMoustafa AE. Comparison of co-presence of Epstein–Barr virus and high-risk human papillomaviruses in colorectal cancers in the Middle East Region, Qatar University Annual Research Forum and Exhibition (QUARFE 2020), Doha, 28 October 2020, DOI: <https://doi.org/10.29117/quarfe.2020.0121>
  104. Gupta I, AlThawadi HA, Skenderi F, Malki MI, **Vranic S**, AlMoustafa AE. Co-Incidence of Human Papillomaviruses and Epstein–Barr Virus is Associated with Advanced Tumor Stage: A Tissue Microarray Study of Head and Neck Cancers", Qatar University Annual Research Forum and Exhibition (QUARFE 2020), Doha, 28 October 2020, DOI: <https://doi.org/10.29117/quarfe.2020.0122>
  105. Bonfil RD, Sohail A, **Vranic S**, Shi D, Chen W, Hang H, Kim HR, Fridman R. Reduced expression of Discoidin Domain Receptor 1 (DDR 1) is associated with high Gleason score and bone metastasis in prostate cancer. HCA-NSU MD Research Day 2020, 6<sup>th</sup> November 2020, link: <https://nsuworks.nova.edu/hcard/2020/day1/93/>
  106. Skenderi F, Alahmad MAM, Alahmad YM, Abdelhafez IHE, Gatalica Z, **Vranic S**. HER2-positive Apocrine Carcinoma of the Breast: A population-based Analysis of Incidence, Treatment, and Outcome. *Virchows Arch* 2020;477:S55  
Note: the 32nd ESP Congress & XXXIII IAP Congress, December 2020.
  107. Gatalica Z, **Vranic S**. Apocrine breast carcinoma from biomarkers to therapy. 8<sup>th</sup> Annual Congress of the European Society for Translational Medicine. 20-26 September 2021 (Virtual), link: <https://eustm-2021.heysummit.com/talks/apocrine-breast-carcinoma-from-biomarkers-to-therapy/>.
  108. Kheraldine H, Gupta I, Al Farsi H, Cyprian FS, **Vranic S**, Al Moustafa AE. The Combination of Dasatinib and PD L1 inhibitor prevents the progression of epithelial mesenchymal transition and dramatically blocks cell invasion of HER2 positive breast cancer cells. Qatar University Annual Research Forum and Exhibition (QUARFE 2021), Doha, 20 October 2021, <https://doi.org/10.29117/quarfe.2021.0105>
  109. Gatalica Z, **Vranic S**. NTRK gene fusions in cancers and their diagnostics. 11<sup>th</sup> Annual Meeting of the Middle Eastern Association for Cancer Research, November 27, 2021, link: <http://www.qu.edu.qa/conference/meacr>
  110. Karin-Kujundzic V, Skrtic A, **Vranic S**, Serman L. SHH and IHH Protein Expression in High-Grade Serous Ovarian Carcinomas. *Mod Pathol* 2022;35(suppl.2):772 (Abstract#717).  
**Note: USCAP 2022 Annual Meeting, March 19-23, Los Angeles, United States**
  111. Gatalica Z, Stafford P, **Vranic S**. Alpha-methylacyl-CoA Racemase (AMACR/P504S) Protein is Upregulated in Early Proliferative Lesions of the Breast Irrespective of Apocrine Differentiation. *Virchows Arch* 2022;481(suppl. 1), PS-01-003, <https://doi.org/10.1007/s00428-022-03379-4>  
**Note: 34<sup>th</sup> European Congress of Pathology, September 3-7, 2022, Basel, Switzerland.**

112. **Vranic S.** Molecular and clinical characteristics of apocrine carcinoma of the breast. Abstract book of the 28<sup>th</sup> Ljudevit Jurak International Symposium on Comparative Pathology, Zagreb, 2022, p. 22 (L9).
113. Abbas, TO, **Vranic S**, Alipour H, Pennisi CP. Age-related changes in the histological and biomechanical properties of the penile urethra in rabbits. 4<sup>th</sup> World Congress of Hypospadias, Sao Paulo, November 16-18, 2022.
114. Kheraldine H, Gupta I, **Vranic S**, Al-Farsi HF, Al Moustafa AE. The Combination of Dasatinib and PD-1/PD-L1 inhibitor prevents the progression of EMT and dramatically blocks cell invasion of HER2-positive breast cancer cells via PI3K/AKT and beta-catenin pathways. The MEACR 12<sup>th</sup> Annual Meeting 2022, page 149, abstract#137.
115. Gatalica Z, Basu G, **Vranic S**. BRAF Mutations and Other Genomic Alterations across Cancers: An Updated Review. The MEACR 12<sup>th</sup> Annual Meeting 2022, page 12.
116. Skenderi F, Glamoclija U, **Vranic S**. Clinicopathologic characteristics of acinic cell carcinoma of the breast. A population-based study. To be submitted, ESMO Breast 2023.